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Abstract
ARGLU1 is a well conserved protein whose function is not well understood. I will show
that ARGLU1 is an alternatively spliced gene, with at least three alternatively spliced isoforms.
The main isoform codes for a nuclear protein that has been associated with the mediator
transcriptional regulation complex as well as components of the spliceosome. One alternative
isoform of ARGLU1 retains a single unspliced intron, even though all other introns have been
removed, and is localized exclusively in the nucleus. A second alternative isoform causes inclusion
of a premature termination codon, and is quickly degraded by the nonsense mediated decay quality
control pathway. Interestingly, the retained intron contains an ultraconserved element, which is
more than 95% conserved between human and chicken for over 500 bases. I will show that this
ultraconserved element plays a key role in the alternative splicing of ARGLU1. Furthermore, I
will show that exogenous overexpression of ARGLU1 leads to dramatic changes in alternative
splicing of its own endogenous mRNA, causing a decrease in the protein coding isoform, and an
increase in the retained intron and nonsense mediated decay targeted isoforms. Additionally,
overexpression of ARGLU1 causes changes in mRNA levels and alternative splicing in a number
of genes. Taken together, these results indicate that ARGLU1 can regulate its own splicing to
regulate cellular protein levels. Furthermore, these results suggest that ARGLU1 plays a role in
cellular alternative splicing.
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Chapter 1
Introduction
1.1 ARGLU1
This paper will focus on the regulation of a protein called Arginine and Glutamate rich
protein 1, hereafter referred to as ARGLU1. The function of ARGLU1 has been poorly described,
but a number of factors indicate that it is of biological importance. First, it has been shown that
depletion of ARGLU1 protein leads to defects in cellular responsiveness to exogenous stimuli such
as estrogen (Zhang et al., 2011). Second, ARGLU1 protein sequence is well conserved through
evolutionary time, indicating a conserved function (Figure 1.1). In addition to this conservation,
ARGLU1 also has a region of extraordinarily high non-coding DNA sequence conservation,
suggesting a consistent selective pressure not only at the level of amino acid sequence (Dimitrieva
and Bucher, 2013). Such highly conserved elements have been shown to have a variety of
important regulatory effects, including transcriptional enhancer activity and regulation of
alternative splicing, which will be discussed below.
ARGLU1 is encoded by a gene located at human chromosome 13q33.3. Initial reports
involving ARGLU1, which was previously annotated as FLJ10154, focused on rare deletions of
the 13q33-34 region that overlap ARGLU1 and are associated with microcephaly, developmental
delay, and genitourinary malformations in males (Andresen et al., 2010; Ballarati et al., 2007;
Brown et al., 1993, 1995; Quélin et al., 2009; Walczak-Sztulpa et al., 2008). While the adjacent
gene EFNB2 was posited to be the gene responsible for these malformations, ARGLU1 is also
deleted in all reports of genitourinary malformations associated with deletions from this region.
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Figure 1.1 ARGLU1 Protein Conservation. Multiple-alignment view of ARGLU1 proteins from
a variety of species, including the frog Xenopus laevis. Serine residues are highlighted in red,
arginine residues in green, and glutamate residues in yellow. Note the enrichment of RS dipeptides
in the N-terminal region, and the enrichment of glutamate in the c-terminal portion of the protein.
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A 2009 study investigating glomerulus specific gene expression in the human kidney
indicated that ARGLU1 was expressed exclusively in the glomerulus, but not in the cortex or
medulla, of the kidney (Cuellar et al., 2009). This study used an RT-PCR based assay to
demonstrate this exclusive expression. Interestingly, this study used primers that amplify an
alternatively spliced form of the ARGLU1 transcript that retains an intron between exons 2-3
(Cuellar et al., 2009), which will be the focus of much of this dissertation. Therefore, this report
would seem to indicate that the intron retained isoform is expressed in a very tissue specific
manner. Other reports have also indicated that the retained intron isoform of ARGLU1 is
alternatively spliced in a tissue dependent manner (Braunschweig et al., 2014).
The most in depth investigation of the function of ARGLU1 protein was made by Zhang
et al. in 2011. This study sought to find novel protein interactions with the Mediator complex
protein MED1 (Zhang et al., 2011). This study identified ARGLU1 as a MED1 interacting protein
through affinity purification of MED1 from MCF7 cells, an estrogen receptor positive breast
cancer cell line, followed by mass spectrometry (Zhang et al., 2011). They further characterized
the protein, finding that it was nuclearly localized, and directly interacts with the C-terminus of
MED1 through its N-terminal arginine-rich domain (Zhang et al., 2011). Interestingly, a different
report analyzing the subcellular localization of proteins throughout the cell cycle demonstrated
that ARGLU1’s nuclear localization was highly dependent on cell cycle stage, peaking in mid-Sphase, and with the lowest nuclear localization during the G1 phase (Sigal et al., 2006). As Zhang
et al. were interested in new regulators of MED1’s role in transcriptional licensing in response to
estrogen, they showed that ARGLU1 was preferentially co-recruited with MED1 to the promoter
of the estrogen responsive genes MYC and pS2, but not the control gene GAPDH, following
estradiol (E2) treatment (Zhang et al., 2011). They further found that shRNA mediated knock

3

down of ARGLU1 or MED1 decreased expression of these E2 responsive genes, but not GAPDH.
Finally, they showed that shRNA-mediated knockdown of ARGU1 mRNA and protein caused
decreased basal and E2 responsive cellular proliferation and anchorage independent colony
formation (Zhang et al., 2011). Taken together, this study indicates that ARGLU1 interacts
specifically with the MED1 component of the mediator complex, and functions to regulate the
expression of at least two important estrogen responsive proto-oncogenes.
1.2 Mediator Complex
Mediator is a large, multi-subunit complex that is involved in licensing of RNA polymerase
II in transcription. Its co-activator function is mediating the interaction of enhancer-bound
transcription factors and activators, which may be bound to distal enhancer regions, with the core
RNA pol II pre-initiation complex located at the core gene promoter region (Poss et al., 2013).
Models of the interaction between the mediator complex and RNA pol II indicate multiple points
of interaction, but perhaps the most interesting is the interaction with the carboxy-terminal domain
of RPB1, the largest subunit RNA pol II, which is composed of 52 heptad repeats that are
extensively and dynamically modified during the transcription cycle (Bentley, 2014). This subunit
of RNA pol II serves as a hub for transient interactions of many proteins, including mediator,
splicing factors, histone modifiers. It serves as a way to functionally link these factors involved
in transcription (Bentley, 2014). Indeed, the MED23 subunit of mediator was recently found to
interact with a number of proteins involved in mRNA splicing and maturation (Huang et al., 2012).
This study focused on the interaction between MED23 and hnRNPL, a gene involved in mRNA
splicing and stability, and found that in the absence of MED23 splicing of a subset of hnRNPLregulated genes was altered (Huang et al., 2012). This mediator-splicing factor interaction,
possibly potentiated by the CTD of RNA pol II, may serve as a model the interplay between
4

transcriptional activators and splicing regulation. Given ARGLU1’s interaction with mediator and
findings, discussed later, that ARGLU1 is involved in alternative splicing, this type of interaction
will be of future interest.
1.3 Ultraconserved Elements
Advances in sequencing technology over the last two decades have laid the foundations for
a number of advances in our understanding of genome biology (Lander et al., 2001; Venter et al.,
2001) including comparative genomic studies that have furthered our understanding of evolution
at the nucleotide level (Waterston et al., 2002). One of the goals of comparative genomics is to
use evolutionary selection as a marker of biological function (Alföldi and Lindblad-Toh, 2013).
An important initial study comparing the human genome with that of mice and rats revealed
hundreds of ultra-conserved elements (UCEs) that they defined as longer than 200 bases of 100%
sequence identity (Bejerano et al., 2004). Subsequent analysis found that a set of similarly highly
conserved non-coding elements functioned as enhancers associated with development (Woolfe et
al., 2005), or clustered near developmentally regulated genes (Lindblad-Toh et al., 2005),
indicating that such conservation can indicate regulatory sequences. Further studies have taken a
slightly different approach, looking for ultra-conserved non-coding sequences over longer
evolutionary time scales; for example sequences that are more than 95% identical and over 200
bases between human and chicken (Dimitrieva and Bucher, 2013). My work has used this standard
of over 95% conserved nucleotide identity over more than 200 bases between human and chicken
to define a UCE.
While one set of highly conserved sequence seems to function in the context of
transcriptional regulatory regions, another subset of UCEs are postulated to have an RNA
regulatory function. One method of analysis of conserved function is to use computational
5

predictions of RNA folding. Indeed, reports using computational folding predictions based on
highly conserved non-CDS regions are able to predict transcribed non-coding RNAs (ncRNA)
with fairly high confidence (Washietl et al., 2005). Another report by the same group was able to
identify ncRNA structural conservation even without filtering based on sequence conservation,
albeit with roughly twice the false positive rate for truly transcribed ncRNAs when compared with
conservation based prediction methods (Washietl et al., 2007). Other studies have found that
sequence conservation is not always a predictor for conserved ncRNA function, good examples
being certain miRNAs, Xist, Air, and H19, which have known and conserved functions but poor
sequence conservation (Bentwich et al., 2005; Pang et al., 2006). So while a high degree of
conservation may predict ncRNA structure and function in some cases, it is not the only predictor.
Another RNA function for non-coding UCEs may be in RNA splicing, processing and
localization. In this context, these highly conserved sequences would be predicted to serve as
RNA cis-elements which would interact with trans-elements, namely proteins and protein
complexes. A notable example of this is the β-actin mRNA, which is localized to the dendrites of
hippocampal neurons (Tiruchinapalli et al., 2003) or other subcellular localizations by an
interaction between a 3’ UTR cis-element called zipcode and the RNA recognition motif (RRM)
and hnRNP K homology (KH) domains of zipcode binding protein 1 (Farina, 2002; Ross et al.,
1997). However, these types of cis/trans interactions are usually on the order of tens of bases.
Indeed the zipcode sequence itself is 54 bases long (Kislauskis et al., 1994), whereas
ultraconserved elements require at least 200 bases of conservation. One could thus hypothesize
that such long cis-elements may be concatenations of binding sites for multiple trans-factors, or
that they coordinate multiple types of regulation, such as splicing, sub-cellular localization,
nuclear-cytoplasmic trafficking and translation.
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Indeed, highly- and ultra-conserved sequences have been associated with conserved and
tissue specific alternative splicing events (Baek and Green, 2005; Lareau et al., 2007; Ni et al.,
2007; Sugnet et al., 2006). Of particular interest are the association between highly conserved
sequences and alternative splicing of many SR and hnRNP proteins, which are themselves
regulators of splicing (Lareau et al., 2007; Ni et al., 2007). It is now well established that these
alternative splicing events are linked with a cellular quality control mechanism known as nonsense
mediated decay (NMD) (Baek and Green, 2005; Lareau et al., 2007; Lewis et al., 2003; Ni et al.,
2007); however another recent study has linked UCE-related intron retention alternative splicing
to a different regulator mechanism that they labeled ‘detained introns’ (Boutz et al., 2015). While
I want to highlight this association between highly conserved sequences and alternative splicing,
I will further discuss the critical splicing-associated proteins regulated by these elements, their
roles in splicing, as well as the mechanisms and outcomes of their alternative splicing in a later
section.
1.4 RNA splicing—Coordination of spliceosome assembly by cis- and trans-acting factors
RNA splicing is a process by which exon sequences from a primary RNA transcript are
brought together, and the intervening introns are removed. This process was first appreciated in
adenovirus (Berget et al., 1977; Chow et al., 1977). Sharp and colleagues observed R-looping of
DNA following hybridization of polyribosome-associated viral RNA to viral DNA treated with
restriction enzymes, and proposed that this was the result of bringing together and joining specific
sequences within large, nuclear viral transcripts (Berget et al., 1977). In a report published just a
month later, Richard Roberts and colleagues reported similar results mapping R-loop interactions,
and concluding that these sequences were not coded linearly by the DNA genome of the virus
(Chow et al., 1977). The report by the Sharp group (Berget et al., 1977), and a separate report by
7

Daniel Klessig (Klessig, 1977), proposed a model that is in line with our current understanding of
RNA splicing, whereby the 3’-end of one segment is brought together with the 5’-end of the next
segment and the intervening sequences are looped out and removed. Shortly thereafter, a number
of groups reported splicing of a wide variety of metazoan genes, including the rabbit (Jeffreys and
Flavell, 1977) and mouse (Tilghman et al., 1978) β-globin genes, the chicken ovalbumin gene
(Breathnach et al., 1977), and the immunoglobulin light chain (Tonegawa et al., 1978).
Development of a method to splice RNA molecules in vitro (Grabowski et al., 1984; Kole
and Weissman, 1982; Krainer et al., 1984; Padgett et al., 1983; Ruskin et al., 1984) allowed for
further dissection and identification of the component sequences of a splicing reaction, namely the
5’-splice site and 3’-splice site (Mount, 1982), and branch point (Konarska et al., 1985). The
splicing reaction came to be understood to be two sequential transesterification reactions. In the
first step, the 5’-splice site, with a consensus sequence of MAG|GURAGU where M is A/C and R
is A/G, is brought into contact with the branch point, an AU upstream of the 3’-splice site, and the
5’ G of the GU dinucleotide is joined by a 2’-5’ phosphodiester linkage to adenosine of the branch
point (Konarska et al., 1985), forming a structure known as a lariat (Padgett et al., 1984). In the
second step of splicing, the 3’-splice site, which has a consensus YAG|G, where Y is a pyrimidine,
is cleaved following the AG, and the 5’-end of the 3’ exon is joined to the 3’-end of the of the
upstream exon by a 3’-5’ phosphodiester bond (Grabowski et al., 1984).
During this same time, it was recognized that snRNP complexes, composed of small
nuclear RNAs (snRNAs), as well as protein components interact with specific sequences on the
RNA (Chabot et al., 1985) and function to mediate the splicing reaction by dynamically bringing
together the mRNA components of the splicing reaction. These snRNP complexes were first
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identified using anti-nuclear antibodies produced by patients with Systemic Lupus Erythematosus
(Lerner and Steitz, 1979).
This dynamic macromolecular complex, called the spliceosome, is characterized by the
formation of a number of distinct complexes that coordinate the two transesterification reactions
of RNA splicing. The first complex formed, complex E, begins with U1 snRNP binding through
U1 mediated base pairing to the 5’-splice site. Additionally during complex E formation, a protein
called splicing factor 1 (SF1) or branch point binding protein (BPB) is recruited to the branchpoint,
and the subunits of the U2 auxiliary factor A2, U2AF65 and U2AF35 (Zamore et al., 1992), bind
to the polypyrimidine tract and the characteristic 3’splice site AG, respectively (Wahl et al., 2009).
Prior to and during this stage proteins, including the SR and hnRNP families, are recruited to the
RNAs through cis-elements and can promote or repress binding of these complex E factors. These
regulatory proteins will be discussed in greater detail in later sections. Complex A is then formed,
with the displacement of SF1/BPB by the U2 snRNP at the branch point (Wahl et al., 2009). Next,
complex B is formed by the recruitment of the U4/U5/U6 tri-snRNP, with U5 base-pairing to the
5’-splice site (Wahl et al., 2009). This leads to destabilization of the complex, and the U1 and U4
snRNPs exit the complex. At the same time, U6 base pairs with the 5’-splice site, displacing U5.
With the hydrolysis of ATP, the catalytic spliceosome is generated and catalyzes the first
transesterification reaction in which the 2’ hydroxyl of the branch point adenosine attacks the 5’
phosphate of the 5’-splice site guanidine, forming the lariat. The complex then rearranges again,
with U5 binding to the 3’-splice site, bringing the upstream and downstream exons together. With
U2/U5/U6 still bound, the free 3’-hydroxyl of the 5’-exon attacks the 5’ phosphate bond of the 3’ss, and the ligation reaction is carried out following ATP hydrolysis. (Will and Lührmann, 2011).
This process is well reviewed elsewhere (Wahl et al., 2009; Will and Lührmann, 2011).
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There is a large body of work that has sought to define the complement of proteins involved
in the spliceosome. One productive system has been affinity purification of proteins and RNAs
associated with different stages of spliceosome assembly followed by mass spectrometry.
Interestingly, ARGLU1 protein has been found in multiple preparations of spliceosome
complexes, including complex A (Behzadnia et al., 2007), the active step 1 spliceosome (Bessonov
et al., 2008), and purified complex B (Deckert et al., 2006). Based on the finding that ARGLU1
was associated with the spliceosome, it was included in a yeast 2-hybrid screen for protein-protein
interactions between spliceosome proteins. In that experiment, ARGLU1 was found to interact
with itself, CHERP, PRMT5, SRPK2, and ZCCHC10 (Hegele et al., 2012). Another high
throughput protein-protein interaction screen, this time in drosophila, found that the ARGLU1
homolog CG31712 was associated with spliceosome components, including the U1-70K protein
and CG4119 (Guruharsha et al., 2011). A high throughput assay of protein kinase targets identified
ARGLU1 as a phosphorylation target of both SRPK1 and SRPK2 protein kinases (Varjosalo et al.,
2013). A list of proteins interacting with ARGLU1 is found in Table 1.1. These interactions are
especially interesting in the context of our experimental findings, as the SRPK protein kinases are
known to regulate SR proteins, an important class of splicing regulators that will be covered in a
later section in more detail. Taken together, these interactions indicate that ARGLU1 interacts
with components of the spliceosome. However, proteomic studies designed to determine the full
array of RNA binding proteins have not provided evidence that ARGLU1 interacts directly with
mRNA (Baltz et al., 2012; Castello et al., 2012).
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physical
ARGLU1
APP
Complex
Two-hybrid
physical
CHERP
ARGLU1
Two-hybrid
physical
ARGLU1
CHERP
Two-hybrid
physical
ARGLU1 ARGLU1
Two-hybrid
physical
ARGLU1
PRMT5
Two-hybrid
physical
ARGLU1 ZCCHC10
Two-hybrid
physical
ARGLU1
SRPK2
Two-hybrid
physical
PRMT5
ARGLU1
Two-hybrid
physical
ZCCHC10 ARGLU1
Two-hybrid
physical
SRPK2
ARGLU1
Biochemical
physical
SRPK2
ARGLU1
Activity
Biochemical
physical
SRPK1
ARGLU1
Activity
Affinity Capturephysical
CUL7
ARGLU1
MS
Affinity Capturephysical
EED
ARGLU1
MS
Table 1.1 Known Protein-Protein interactions for ARGLU1
IKBKG

ARGLU1
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Author

Pubmed
ID

Fenner BJ (2010)

20098747

Abdelmohsen K
(2009)
Behzadnia N
(2007)
Neganova I
(2011)

19322201
17332742
21319273

Olah J (2011)

21832049

Hegele A (2012)
Hegele A (2012)
Hegele A (2012)
Hegele A (2012)
Hegele A (2012)
Hegele A (2012)
Hegele A (2012)
Hegele A (2012)
Hegele A (2012)
Varjosalo M
(2013)
Varjosalo M
(2013)

22365833
22365833
22365833
22365833
22365833
22365833
22365833
22365833
22365833

Hanson D (2014)

24711643

Cao Q (2014)

24457600

23602568
23602568

1.5 Intron and Exon Definition
There are two models for how initial assembly of the spliceosome components occurs:
intron definition and exon definition. The intron definition model posits that components of the
spliceosome assemble and interact across small introns (Talerico and Berget, 1994), where the 5’
and 3’ splice sites are close to each other in space. In vitro and transfection splicing assays have
shown that as intron length rises above 250 nucleotides, splicing becomes quite inefficient (FoxWalsh et al., 2005). This same study found that increased inclusion of human alternatively spliced
exons was associated strongly with a shorter upstream intron (Fox-Walsh et al., 2005).
Furthermore, this study found that inclusion of an RNA cis-element known as an exonic splice
enhancer (ESE) could dramatically increase splicing efficiency of even longer introns (Fox-Walsh
et al., 2005). While intron definition mediated splicing seems to be the exception rather than the
rule in mammals, it is seen almost exclusively in plants, fungi and invertebrates (Talerico and
Berget, 1994; Xiao et al., 2007). Consequently, vertebrates have developed a complex set of
regulatory elements to enforce the correct usage of exons within the context of long introns that
often contain pseudoexons with paired 3’- and 5’-splice sites (Xiao et al., 2007). These elements
will be discussed further below.
The second model for assembling spliceosome components is called exon definition, and
occurs by the assembly of snRNP complexes to either end of an exon (Robberson et al., 1990;
Sterner et al., 1996). These assembled mRNA/snRNP complexes can then form associations
across introns mediated by interactions between snRNPs and other splicing associated proteins.
The exon definition model is supported by evidence that U1 snRNP binding to the 5’ss of an exon
stimulated splicing of the upstream 5’ss to the 3’ss of that exon (Kuo et al., 1991). It was found
that polypyrimidine tracts play an important role in potentiating the exon definition model by
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recruiting important protein factors such as U2AF (Dominski and Kole, 1992; Talerico and Berget,
1994). Similar to the intron definition model, there appears to be a size limit to the exon definition
model, with failure of exon definition by in vitro splicing inclusion of exons larger than
approximately 300 bases (Robberson et al., 1990), while exons larger than approximately 500
bases are poorly included in transfection splicing studies, especially in the context of long introns
(Sterner et al., 1996). Thus, there seem to be limits on the size of either exons or introns for their
definition in splicing.
Early studies indicated that there is also a lower size limit for exon definition of
approximately 50 nt (Dominski and Kole, 1991), although inclusion of small exons could be
modulated by altering the splice site strength or upstream polypyrimidine tract and branch point
(Dominski and Kole, 1991, 1992). The use of high throughput RNA sequencing techniques has
allowed for the identification of a large number of 3-27 nt small exons, which they have termed
microexons, which are used in neurons and are misregulated in the autistic brain (Irimia et al.,
2014). Interestingly, there have been a number of groups that have identified zero length exons,
which function in the splicing of exceptionally long exons in drosophila (Burnette, 2005; Duff et
al., 2015; Hatton et al., 1998) and humans (Duff et al., 2015; Sibley et al., 2015) through a process
called recursive splicing where the removal of an intron regenerates a 5’ss that can be used for
further splicing. These types of events have challenged the classical concept of an exon, as they
are simply the juxtaposition of a 3’ and 5’-splice site.
1.6 Alternative splicing
One of the earliest reported examples of RNA splicing was the human immunoglobulin
light chain (Tonegawa et al., 1978). Soon after this discovery, the immunoglobulin gene played
an important role in understanding how RNA splicing lead to the incredible diversity of molecules
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derived from this locus (Alt et al., 1980; Early et al., 1980) through a process known as alternative
splicing (AS), whereby a precursor RNA (pre-mRNA) transcript can be processed to include or
exclude exons in the final mature mRNA. Alternative splicing plays a number of important roles
in cells, including expanding the protein repertoire of cells (Nilsen and Graveley, 2010), allowing
temporal and tissue specific control of protein expression (Wang et al., 2008), and response to
cellular stimuli (Braunschweig et al., 2013). AS seems to be an important and widely used
mechanism, as recent studies have concluded that approximately 95% of all genes in the human
genome generate more than one spliced isoform (Pan et al., 2008; Wang et al., 2008).
Technological advances in the past two decades such as microarray and more recently RNA-Seq
technologies have allowed for mapping and quantitation of an ever increasing number of
alternatively spliced RNAs across a host of species.
There are a number of common types of alternative splicing (Fig 1.2). Most common is
the cassette exon, which is a simple inclusion/exclusion event. Other types include alternative 5’splice site, alternative 3’-splice site, mutually exclusive exon usage, and intron retention. More
complex sets of alternative splicing can be created by combining these types of alternative events.
An example relevant to our study is the combination of an intron retention event and a cassette
exon with alternative 5’-splice sites on the cassette exon. It is easy to see how this can rapidly
increase the number of isoforms derived from one pre-mRNA.
Alternative splicing is regulated by the interactions between cis-elements within RNA
molecules and trans-acting proteins that bind to these RNA sequences. We will discuss the details
of these regulatory elements below.
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Figure 1.2 Types of alternative splicing. The various types of alternative splicing are depicted
in cartoon form. Constitutive exons are colored blue, while alternative exon are colored to
differentiate them.
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1.7 Cis-elements regulating splicing
The exon definition process, discussed earlier, is modulated through the interaction of cisacting RNA elements with trans-acting proteins, such as SR or hnRNP proteins (Caceres et al.,
1994). The cis-elements that inform exon definition, generally known as Splicing Regulatory
Elements (SREs), can be defined as exonic splice enhancers of suppressors (ESEs or ESSs) or
intronic splice enhancers or silencers (ISEs or ISSs), based on their location and propensity to
promote or suppress inclusion of the associated exon (Wang and Burge, 2008). The 5’- and 3’consensus splice sites are only 9 bases and 4 bases, respectively, and thus found quite frequently
in the genome. Furthermore, the introns separating these sequences are often hundreds or
thousands of bases long, making these cis-elements critical for more specificity in the recruitment
of the core spliceosomal components (Wang and Burge, 2008).
Many studies have defined cis-elements using a variety of techniques. Classic studies
identified individual cis-elements through molecular biology techniques such as mutagenesis and
deletion of specific sequences proximal to regulated exons within minigene reporters (Schaal and
Maniatis, 1999; Sun and Chasin, 2000). Other SREs have been deduced from pathogenic SNPs
linked to modification of splicing, notably in the CFTR gene (Pagani et al., 2003), and the SMN2
gene (Cartegni and Krainer, 2002).

However, high throughput screens and computational

approaches have led to more general identification of SREs. For example, cloning of random
sequences into the middle exon of multi-exon reporters followed by selection for inclusion of that
exon has been used to identify ESE sequences in both in vitro (Tian and Kole, 1995) and in vivo
splicing assays (Coulter et al., 1997), both of enriched for purine-rich sequences, similar to analysis
of individual ESEs that had been found to interact with SR proteins (Dirksen et al., 1994;
Lavigueur et al., 1993; Lynch and Maniatis, 1995; Tanaka et al., 1994). Another useful high
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throughput approach has been to split green fluorescent protein with an internal exon that disrupts
its fluorescence. The inclusion or exclusion of this internal exon can be modulated by insertion of
random sequences within either the exon or in adjacent introns. This system was first used to
screen random decamers for their ability to cause skipping of the internal exon and thus green
fluorescence, indicating their ability to function as ESSs (Wang et al., 2004). More recently, this
same group has used a similar approach to screen both ISSs (Wang et al., 2013) and ISEs (Wang
et al., 2012). The information gained from such high-throughput screens can then be applied to
predict splicing regulation of other exons.
1.8 Trans-acting Splicing Regulators
These cis-elements act through interactions with trans-acting proteins that serve to promote
or inhibit spliceosome subunit binding, based on the RNA element and the protein recruited (Wang
and Burge, 2008). These trans-acting proteins mostly fall into two large classes of proteins,
although there are other splicing regulatory proteins that do not easily fit into either class (Fu and
Ares, 2014). Early studies showed that stereotypical proteins within these two families of proteins,
SR proteins and hnRNP proteins, had generally antagonistic effects on the inclusion of
alternatively spliced exons (Caceres et al., 1994; Mayeda and Krainer, 1992; Mayeda et al., 1994),
although more recent studies have indicated a more nuanced effect of these proteins on exon
inclusion/exclusion (Huelga et al., 2012; Pandit et al., 2013).
The first class of trans-acting regulators are the hnRNP proteins, which are generally held
to have an inhibitory role in exon inclusion. The most well studied hnRNP proteins have been
shown to have splicing inhibitory roles, and include hnRNPA/B family (Mayeda and Krainer,
1992; Mayeda et al., 1994; Yang et al., 1994) as well as polypyrimidine tract-binding protein
(PTB) (Singh et al., 1995). The mechanism by which these proteins cause inhibition of exon
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inclusion is still unclear, although recent studies have begun to explain their effects. Studies have
proposed that hnRNP A/B initially bind to ISS or ESS sequences and subsequently oligomerize to
cover nearby RNA sequences, thereby preventing binding of SR proteins that promote splicing
(Okunola and Krainer, 2009; Zhu et al., 2001). A recent study sought to understand the genes
regulated by a variety hnRNP proteins in human cells. They used both siRNA mediate knockdown
to identify alternative splicing events regulated by these proteins, as well as a technique known as
CLIP-seq to map the interactions between the hnRNP proteins and their target RNAs, which
revealed (Huelga et al., 2012). This study produced a number of interesting results, including the
fact that knockdown of hnRNP proteins caused the increased or decreased inclusion of a large
number of cassette exons, indicating that hnRNP proteins are not exclusively inhibitory, but play
a more complicated role in balancing the usage of certain exons. Furthermore, they presented
evidence for hnRNPs cross-regulating other RNA binding proteins, including other hnRNPs and
SR proteins (Huelga et al., 2012).
PTB is another RNA binding protein generally thought to be inhibitory to exon inclusion
which has been shown to interact with intronic polypyrimidine tracts upstream of 3’-splice sites
(Singh et al., 1995) and is proposed to block cross-intron interactions between the 5’- and 3’-splice
sites after assembly of the A complex and exon definition (Sharma et al., 2005, 2008).
Additionally, PTB has been shown to interact directly with U1 at the 5’ss and stabilizing the
interaction (Sharma et al., 2011). This particular study may be of further interest, as it suggests a
mechanism for inhibiting splicing of upstream and downstream exons over long distances, by
locking them in a conformation that does not allow progression beyond the spliceosomal E
complex, thus stalling the splicing reaction (Roca et al., 2013). Deletion of the mouse homolog of
PTB, Ptbp1, was shown to regulate a number of neuron specific intron retention events, causing
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the nuclear retention of these transcripts (Yap et al., 2012). Other studies have shown that binding
of SR protein SRSF7 to intronic regions downstream of exons will inhibit their splicing by
preventing progression beyond the spliceosomal E complex, while still allowing recruitment of U1
to the 5’-splice site (Erkelenz et al., 2013), perhaps suggesting a similar role to PTB. The role of
hnRNPs seems to be complicated, and may range from negatively modulating the recruitment of
spliceosome components through competition with SR proteins to inhibiting the rearrangement of
these components into a committed complex.
The second large family of splicing regulatory proteins are known as SR proteins (for
serine/arginine-rich proteins). SR proteins take their name as the result of a characteristic Cterminal RS domain, which is enriched in clustered Serine-Arginine dipeptides. Furthermore,
these proteins have one or two N-terminal RNA-recognition motifs (RRMs), similar to many other
RNA binding proteins including hnRNP proteins (Bandziulis et al., 1989; Zahler et al., 1992).
These proteins are known to localize to subnuclear bodies known as splicing speckles, which are
repositories for splicing factors (Spector et al., 1991). Furthermore, the function and localization
of SR proteins is regulated by the phosphorylation state of their RS domains (Cáceres et al., 1997),
which is dependent on multiple protein kinases, including SRPK1 (Gui et al., 1994), SRPK2
(Wang et al., 1998), and the CLK kinases (Colwill et al., 1996), as well as long non-coding RNAs
such as MALAT1 (Tripathi et al., 2010).
The presence and function of the SR family of proteins was first recognized in the
Drosophila development system, where a cascade protein factors regulate sex determination
through auto-regulatory splicing as well as alternative splicing of the downstream transcripts
(Amrein et al., 1988, 1994; Bell et al., 1988; Boggs et al., 1987; Goralski et al., 1989). Shortly
thereafter, a number of human proteins were found that shared protein sequence and functional
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similarities to the splicing regulators found in Drosophila, such as ASF/SF2 (Ge and Manley,
1990; Ge et al., 1991; Krainer et al., 1991; Mayeda and Krainer, 1992), now known as SRSF1, and
SC-35 (Fu and Maniatis, 1992a), now known as SRSF2. It was recognized that these SR proteins
interact with cis-elements, the SREs discussed earlier, to carry out their regulatory role (Dirksen
et al., 1994; Sun et al., 1993). SR proteins have been shown to interact with each other, as well as
other RS domain containing proteins such as the U1 snRNP (Wu and Maniatis, 1993).
Furthermore, SR proteins seems to have overlapping ability to interact with other proteins to
potentiate splicing, as they can functionally complement each other (Fu et al., 1992). Additionally,
SR proteins can interact with U1 snRNP and U2AF proteins to recruit them to the 5’ (Kohtz et al.,
1994; Wu and Maniatis, 1993) and 3’-splice site (Fu and Maniatis, 1992b), respectively, and
promote exon definition as discussed earlier. Interestingly, the RS domains of SR proteins can
still function to potentiate splicing independent of the RRM domain, when tethered to pre-mRNAs
(Graveley and Maniatis, 1998; Graveley et al., 1998). Thus, a general model of SR proteins has
their RRMs mediating RNA binding specificity, while their RS domains allow for protein-protein
interactions important for exon definition and spliceosome assembly.
Other proteins involved in regulation of splicing are expressed in tissue specific patterns,
allowing for activation of alternative splicing programs important for cellular specialization. Most
notably, trans-acting proteins such as the NOVA (Licatalosi et al., 2008; Ule et al., 2003; Yano et
al., 2010; Zhang et al., 2010), and RBFOX (Li et al., 2014; Weyn-Vanhentenryck et al., 2014; Yeo
et al., 2009) protein families, and tissue specific SR proteins such as nSR100 (Calarco et al., 2009;
Irimia et al., 2014) compete to bind nascent RNAs at specific motifs and drive regulation of
alternative splicing in a tissue and developmentally regulated manner.
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Several recent studies have employed a variety of techniques to identify splicing events
regulated by SR proteins. The use of high throughput techniques such as RNA splicing-specific
microarrays and RNA-seq experiments have helped to understand the subset of splicing events
regulated by specific SR proteins. Furthermore, techniques such as CLIP-seq have allowed for
high throughput identification of RNAs bound by these proteins. For example, the cellular RNAs
bound by SRSF1 were mapped using CLIP-Seq, which revealed that this protein interacts with
predominantly mRNAs at the exon-intron border, but also binds a variety of other cellular RNAs,
including lncRNas and intronless genes (Sanford et al., 2009). Another example of CLIP-seq
being used to understand the regulatory landscape of SR proteins is the mapping binding sites of
SRSF3 and SRSF4 (Ankö et al., 2010; Änkö et al., 2012), which showed that these two SR proteins
bind distinct subsets of RNA, and preferentially regulate different types of splicing events.
1.9 NMD and splicing
One role of alternative splicing seems to be the regulation of transcript abundance through
cellular RNA decay pathways, notably the Nonsense-Mediated Decay (NMD) pathway. NMD is
a cellular quality control pathway that degrades RNA transcripts that contain premature
termination codons (PTCs), which if translated result in truncated proteins. The ability of PTCs
to cause RNA stability was first recognized in yeast (Losson and Lacroute, 1979). Subsequently,
it was recognized that patients with thalassemia resulting from frame shifting mutations leading to
PTCs caused rapid turnover of RNA, but this turnover could be repressed with the translational
inhibitor actinomycin D (Kinniburgh et al., 1982; Maquat et al., 1981). PTCs may arise from a
number of sources, including DNA mutations, inaccurate transcription leading to frameshifts or
single nucleotide nonsense mutations, or from alternative splicing that puts stop codons in frame
in an inappropriate position.
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One of the key factors in NMD is a multi-subunit complex known as the Exon Junction
Complex (EJC), which, as its name implies, marks the junction between two exons resulting from
splicing. The EJC is deposited upstream of splicing junctions in a sequence-nonspecific manner
mainly through the interaction between the spliced RNAs and eIF4AIII (Shibuya et al., 2004), a
DExH/D RNA helicase which is deposited during the second step of RNA splicing (Zhang and
Krainer, 2007) and acts as a scaffold for the further association of other proteins such as Magoh
and Y14. The EJC is important for a number of cellular processes, such as nuclear export and
subcellular localization (Schell et al., 2002) as well as translation (Nott et al., 2003, 2004; Wiegand
et al., 2003). Most importantly for this discussion, however, it acts as an important scaffold for
the NMD machinery, as the critical NMD factors UPF3 is added during splicing, and is joined by
UPF2 in the cytoplasm (Chamieh et al., 2008; Le Hir et al., 2001; Kervestin and Jacobson, 2012).
During the pioneer round of translation of a transcript with a PTC, the ribosome will cause
a change in the protein composition of the mRNP, displacing the compliment of proteins that
accompanied the mRNA out of the nucleus, including the EJC (Ishigaki et al., 2001; Lejeune et
al., 2002). If the ribosome recognizes a stop codon during translation, it recruits release factors,
such as eRF1 and eRF3, which are associated with the NMD-associated protein UPF1. If the stop
codon is more than ~50 nt upstream of the EJC (i.e., a PTC), a stable interaction will take place
between UPF1 and UPF2, bridging UPF1 with the EJC. This in turn leads to phosphorylation of
UPF1 and recruitment of either SMG6, an endonuclease that cleaves the NMD targeted RNA, or
the SMG5-SMG7 complex that is associated with uncapping and deadenylation of RNAs. Either
of these pathways leads to rapid degradation of the targeted RNA.
As mentioned previously, NMD is coupled to splicing in a number of ways. First, it is the
act of splicing that deposits the EJC on mRNAs. However, another important link may be that
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alternative splicing can lead to the regulated inclusion of PTCs that lead to preferential degradation
of certain gene transcripts over others. This may represent a method of regulation that is dependent
on alternative splicing rather than transcriptional regulation. Interestingly, this mechanism seems
to be especially common in the regulation of splicing factors including SR proteins and hnRNP
proteins (Lareau et al., 2007; Ni et al., 2007; Saltzman et al., 2008).
This link between NMD and alternative splicing was first appreciated in a genome wide
manner when a comprehensive study of expressed sequence tags (ESTs) found that a number of
alternatively spliced genes were found to have isoforms that would be predicted to be subject to
NMD (Lewis et al., 2003). These authors termed this phenomenon regulated unproductive splicing
and translations (RUST). They extended this line of inquiry further, and showed that any of these
alternative splicing events were also conserved between human and mouse (Baek and Green,
2005), and that AS of these predicted NMD targets was linked with the presence of ultra- or highlyconserved elements at the sites of alternative splicing, especially in SR and hnRNP proteins
(Lareau et al., 2007; Ni et al., 2007). Further detailed experimental evidence also showed that
specific SR proteins, including SRSF1 (Sun et al., 2010) and SRSF2 (Sureau et al., 2001),
produced NMD-sensitive splice isoforms that were modulated by overexpression of the protein
coding transcripts. Taken together, these data indicate that there is a conserved regulatory system
of splicing factors that takes advantage of NMD to post-transcriptionally modulate protein levels.
1.10 Retained and Detained introns
Intron retention is a specific type of alternative splicing that has been poorly studied until
recently. It is characterized by the lack of removal of an intron in an otherwise processed
transcript. Retained introns can shape the fate of RNAs in a number of ways, including inhibiting
nuclear export (Nott et al., 2003), causing NMD through the inclusion of an in-frame PTC (Ge and
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Porse, 2014), as well as altering coding potential (Bell et al., 2008, 2010; Buckley et al., 2011;
Dirksen et al., 1995). The regulation of intron retention seems to be complex, with the interactions
of a number of SREs, and thus necessarily their interacting trans-factors. However, there are a
number of important regulatory elements. Perhaps most obviously, informatics studies have
indicated that weak 5’ and 3’-splice sites are correlated with intron retention (Sakabe and de Souza,
2007). It has also been recognized that multiple 5’ss-like sequences (i.e., complementarity to U1)
in close proximity can compete with each other (Pagani et al., 2002; Siebel et al., 1992).
Furthermore, a number of ESS sequences identified in high throughput screens have been
associated with increased intron retention (Wang et al., 2004). One of the most important transfactors important for intron retention is PTB, which has been shown in a number of studies to be
associated with intron retention, both by in vitro experiments (Marinescu et al., 2007; Sharma et
al., 2005, 2008, 2011), and in the effect of animal knock out models (Yap et al., 2012).
This form of alternative splicing was thought to be less common than other types in
mammals (Galante et al., 2004; Michael et al., 2005), and more common in single celled
eukaryotes (Parenteau et al., 2011) and plants (Ner-Gaon et al., 2004), and is critical for many
viruses (Li et al., 2006). However, a number of recent studies have revealed that this type of
alternative splicing is more widespread than initially thought. First, intron retention has been seen
in a number of cancers (Dvinge and Bradley, 2015; Simon et al., 2014; Sowalsky et al., 2015;
Zhang et al., 2014). There have been a number of proposed mechanisms for this increased intron
retention, including global increases in transcription levels leading to saturation of the splicing
machinery (Sowalsky et al., 2015) or changes in histone methylation as the result of SETD2
mutation (Simon et al., 2014). However, intron retention seems to play other, more regulated roles
as well. For example, recent studies have shown that intron retention is regulated in a tissue
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specific and developmentally regulated manner (Braunschweig et al., 2014). T cells demonstrate
intron retention in a specific set of genes that is regulated by hnRNPLL (Cho et al., 2014).
Additionally, granulocyte development causes a regulated intron retention in 86 genes linked to
NMD degradation of those mRNAs (Wong et al., 2013).
As mentioned previously, transcripts with retained introns often have PTCs that are
associated with regulation by NMD. While this seems to be an important mechanism to regulate
protein levels through alternative splicing, a recent study has demonstrated that a large number of
polyadenylated transcripts with retained introns localize to the nucleus, are not degraded by NMD,
and can undergo induced splicing following cellular stress or treatment with an inhibitor of the Clk
family of kinases (Boutz et al., 2015). The authors label RNAs with these characteristics “detained
introns,” and suggest that they may represent a mechanism for storing transcripts for rapid splicing
and export. Importantly to the current study, ARGLU1 was identified as a “detained intron”
transcript in both human and mouse cells.
1.11 Conclusion
In this introduction, I have tried to present context for the rest of the dissertation. To
summarize, ARGLU1 is a nuclearly localized protein. ARGLU1 transcripts have been previously
reported to be alternatively spliced in a number of ways, including the presence of a retained intron.
ARGLU1 protein interacts with members of the mediator complex as well as the spliceosome. In
this dissertation, I will investigate the cis-regulatory landscape of ARGLU1 alternative splicing.
Furthermore, I will present evidence that ARGLU1 protein can function to homeostatically
regulate its own level by feeding back and altering splicing of its own transcript.
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Chapter 2: ARGLU1 Alternative Splicing is Regulated by the Presence of an
Ultraconserved Element
2.1 Introduction
In this chapter I will explore the regulation of alternative splicing of transcripts from the
gene ARGLU1. ARGLU1, previously known as FLJ10154, is a gene with a poorly defined cellular
function. The most in depth study describes ARGLU1’s interaction with a protein called MED1,
a component of the mediator complex (Zhang et al., 2011). The mediator complex functions to
bring the transcriptionally poised RNA pol II complex into contact with transcription factors, thus
allowing transcription to proceed. In their 2011 study, Zhang et al. demonstrated that in the context
of estrogen receptor (ER) dependent MCF7 cells, ARGLU1 potentiated increased expression of
the ER responsive genes MYC and pS2, but not the housekeeping gene GAPDH, after treatment
with estradiol (Zhang et al., 2011). Furthermore, shRNA-mediated knockdown of ARGLU1 led
to a decrease in the growth and adhesion-independent survival of MCF7 cells, with and without
estrogen stimulation (Zhang et al., 2011).
Interestingly, other reports indicate a possible role for ARGLU1 in a different cellular
context, namely in RNA splicing. ARGLU1 protein has been found in multiple preparations of
spliceosome complexes, including complex A (Behzadnia et al., 2007), the active step 1
spliceosome (Bessonov et al., 2008), and purified complex B (Deckert et al., 2006). Additionally,
ARGLU1 has been found to interact with (Hegele et al., 2012), and be phosphorylated by
(Varjosalo et al., 2013), multiple members of the SRPK family of protein kinases, which regulate
a family of proteins important for splicing, known as SR proteins (Aubol et al., 2013; Wang et al.,
1998; Zhong et al., 2009). Additionally, the Drosophila homolog of ARGLU1, CG31712, has
been shown to associate with U1-70K (Guruharsha et al., 2011), a key player in the assembly of
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the spliceosome that has previously been shown to interact with SR and SR-like proteins
(Blencowe et al., 2000; Fu and Maniatis, 1992b; Park et al., 2004).
Alternative splicing is a process by which a precursor mRNA (pre-mRNA) can be
assembled with the inclusion or exclusion of certain exons, leading to multiple mature mRNAs.
As discussed previously, regulation of alternative splicing is mediated by interactions between ciselements within the RNA molecules and trans-acting protein complexes that recognize and bind
to these cis-elements. The cis-elements that inform exon definition, generally known as Splicing
Regulatory Elements (SREs), can be defined as exonic splice enhancers of suppressors (ESEs or
ESSs) or intronic splice enhancers or silencers (ISEs or ISSs), based on their location and
propensity to promote or suppress inclusion of the associated exon (Wang and Burge, 2008). There
have been a number of techniques used to identify cis-elements regulating splicing. Studies
originally identified these sequences through pathogenic mutations in diseases such as cystic
fibrosis, in the CFTR gene (Pagani et al., 2003), and spinal muscular atrophy, in the SMN2 gene
(Cartegni and Krainer, 2002). Other individual cis-elements were discovered through molecular
biology techniques such as mutagenesis and deletion of specific sequences proximal to regulated
exons within minigene reporters (Schaal and Maniatis, 1999; Sun and Chasin, 2000).
The alternative splicing of a number of SR proteins has been correlated with the presence
of ultra-conserved or highly-conserved elements within the primary transcripts of a number of
their genes, including SRSF1, SRSF2, SRSF4, SRSF4, SRSF5, SRSF6, SRSF7, SRSF9, SRSF10,
and SRSF11 (Lareau et al., 2007; Ni et al., 2007) as well as the genes for the hnRNP proteins
HNRPDL, HNRPH1, HNRPK and HNRPM (Ni et al., 2007). These studies correlated these highly
conserved sequences with alternative splicing isoforms that were subject to NMD, as knockdown
of the core NMD factor UPF1 (Lareau et al., 2007; Ni et al., 2007) or treatment with the
27

translational inhibitor emetine (Ni et al., 2007) led to increased levels of inclusion of these exons
containing the premature termination codons (PTCs) that trigger this RNA decay pathway. A 2010
study found that overexpression of SRSF1 regulated splicing of its own transcript to increase the
usage the NMD linked splice isoform, which was within a UCE (Sun et al., 2010). SRSF2 (SC35)
was also shown to regulate its own alternative splicing by upregulating inclusion of a cassette exon
or splicing out of a retained intron, both in the 3’ UTR, and thereby inducing NMD (Sureau et al.,
2001), both of which are associated with highly conserved sequences. These studies concluded
that the presence of exceptionally highly conserved sequences is associated with alternative
splicing coupled to NMD allowing for autoregulation.
One characteristic of ARGLU1 alternative splicing I will explore in this chapter is a retained
intron, where the levels of one intron are much higher than all other introns in the gene.
Additionally, I will show that the transcripts with this retained intron are localized to the nucleus.
A recent study has defined a whole class of RNAs that have these same characteristics, retained
introns and nuclear localization, which they have defined as ‘detained introns’ (Boutz et al., 2015).
Notably, the majority of these detained intron transcripts were not regulated by NMD (Boutz et
al., 2015). ARGLU1 was identified as a ‘detained intron’ containing transcript in both mouse and
human (Boutz et al., 2015). This study also found that the levels of intron retention in a subset of
these detained intron transcripts could be altered through certain treatments, such as DNA
damaging agents or chemical inhibition of Clk kinases (Boutz et al., 2015), which phosphorylate
SR proteins in the nucleus (Aubol et al., 2013; Colwill et al., 1996). Furthermore, it has been
reported that the SR proteins SRSF1 and SRSF2 have a number of retained intron isoforms that
localize to the nucleus and are thought to contribute to homeostatic control of protein abundance
of that gene (Sun et al., 2010; Sureau et al., 2001).

28

The recent development of tools for targeted genome manipulation, including the
Cas9/CRISPR system, has led to methods for manipulating genomic DNA sequences with ease.
Cas9/CRISPR is a bacterial adaptive defense against foreign nucleic acids that functions through
an RNA guided nuclease. This system has been co-opted for use in mammalian systems, and in
the most basic iteration allows for simple targeting of double stranded DNA (dsDNA) breaks. The
most common repair pathways for dsDNA breaks is non-homologous end joining, a low fidelity
repair system that often leads to insertions or deletions of nucleotides at the site of the dsDNA
break.
The hypothesis explored in this chapter is that the ultraconserved element within the
retained intron of ARGLU1 has a regulatory role in alternative splicing of this RNA. I will
explore the role of this UCE in a number of different ways, including direct mutagenesis of a
splicing minigene, Cas9/CRISPR mediated mutagenesis of the genomic loci, and an assessment of
the role of splice site strength in the alternative splicing of this gene.
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2.2 Results
2.2.1 ARGLU1 is alternatively spliced and partitions to the nucleus or cytoplasm depending
on alternative splicing
I initially identified ARGLU1 as partitioning to the nucleus through RNA-Seq data from
HeLa cells that had been fractionated into cytoplasmic and nuclear pools and poly(A) selected
(LLC, LY, and GC, data not shown). A polyadenylated ARGLU1 transcript containing a single
retained intron, but otherwise fully spliced, was found exclusively in the nuclear fraction of cells
I investigated (Figure 2.1). The fully spliced isoform (see Figure 2.2 for an overview of the splice
isoforms) is seen in both the nucleus and cytoplasm by RNA-Seq (Figure 2.1), RT-PCR (Figure
2.3) as well as northern blot (Figure 2.4). As mentioned previously, a number of transcripts with
these characteristics have been identified, and have been termed detained introns (Boutz et al.,
2015).
A minor alternative splicing product has also been observed and annotated previously in
the Ensembl gene annotation database (Cunningham et al., 2014). This isoform includes an
alternative exon that lies within the retained intron. The inclusion of this exon would be predicted
to cause degradation by NMD, as it causes a premature termination codon (PTC). Initial RT-PCR
experiments see little evidence of inclusion of this isoform (Figure 2.3), possibly the result of rapid
degradation by NMD. I will address the degradation of transcripts including this exon in section
2.2.6.

Furthermore, experiments below indicate that the presence of this alternative exon

influences the level of intron retention. Furthermore, I see increased usage of this exon under
conditions of ARGLU1 overexpression, which will be explored further later in this report.
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Figure 2.1 A transcript with a retained intron is localizes to the nucleus and is associated
with an ultraconserved element. RNA-seq reads from nuclear and cytoplasmic fractions of HeLa
cells are aligned to the RefSeq gene annotation for ARGLU1. Nuclear reads are presented in red,
while cytoplasmic reads are in blue. Below the gene annotations is a view from the evolutionary
conservation browser (Ovcharenko et al., 2004). In this view orange represents regions of
nucleotides that are more than 97% conserved with human for over a 200 base window, dark blue
indicates conserved coding regions, and green indicates simple repeats. I have noted the length of
the regions that are 97% conserved between human and the species indicated.
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Figure 2.2 Overview of the ARGLU1 isoforms studied in this dissertation. This cartoon view
of the gene architecture of ARGLU1 and the splice isoforms derived from the pre-mRNA. The
fully spliced RNA has 4 exons, and is exported to the cytoplasm. The retained isoform contains 4
exons as well as the retained intron 2, and is located in the nucleus. The alternative exon included
isoform is quickly degraded by NMD because it contains a premature termination codon, indicated
by a red circle.
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Figure 2.3 RT-PCR confirms that the ARGLU1 intron retained isoform is present exclusively
in the nucleus. A. RT-PCR was performed on nuclear and cytoplasmic fractions of the indicated
cell types. NEAT1 is a lncRNA that is seen exclusively in the nucleus, and RPS19 primers cross
a splice boundary and indicate the fully spliced isoform is localized exclusively in the cytoplasm.
B. Primers used for RT-PCR of ARGLU1. Primer set 1 is Ex2+Ex3 primers. Primer set 2 is
Ex2F+IntR. Primer set 3 is Ex3R+IntF.
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Figure 2.4 Western Blot and Northern Blot indicate that the ARGLU1 retained intron
isoform is localized exclusively in the nucleus. The top panel is a western blot against the nuclear
marker TATA Binding Protein (TBP) and the cytoplasmic marker GAPDH in either total lysate
or nuclear and cytoplasmic fractions of HEK-293 cells. Cells were fractionated as in Figure 2.2.
The bottom panel is a northern blot using a probe that detects both the spliced and retained intron
isoforms. The spliced and retained intron isoforms are indicated in cartoon form on the right.
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2.2.2 ARGLU1 contains an Ultraconserved Element (UCE)
In order to identify sequences within this alternatively spliced intron I hypothesized that
evolutionary conservation could serve as a marker for biological function.

Based on this

hypothesis, I queried databases of highly evolutionarily conserved sequences. Indeed, a region
within the ARGLU1 intron has been previously identified as an ultraconserved element by the
UCNEbase, a database of Ultraconserved Noncoding Elements which identified UCEs as stretches
of nucleotides 95% conserved for over 200 bases between human and chicken (Dimitrieva and
Bucher, 2013). This represents a base substitution rate of approximately 1% per 100 million years,
and sequences fulfilling these stringent requirements have been previously found to only exist in
vertebrates (Retelska et al., 2007). Using UCNEbase and the Evolutionary Conserved Browser
(Ovcharenko et al., 2004), I was able to identify an ultraconserved region of 500 bases that fit these
requirements (Figure 2.1). This region is 95% conserved at the nucleotide level between human
and chicken for 500 bases, and 95% conserved with the frog xenopus tropicalis for 265 bases
(Figure 2.1). Notably, using the more strict definition of a UCE set out by Bejarano et al (Bejerano
et al., 2004), which required 100% conservation for over 200, the ARGLU1 UCE is 100%
conserved between human and chicken for 228 bases.
2.2.3 The UCE in ARGLU1 intron 2 is a cis-regulatory element controlling intron retention
The observation of the UCE located within the retained intron led us to hypothesize that
this element is regulating this alternative splicing event. To test this in an experimentally tractable
manner, I created a splicing reporter vector comprised of the retained intron as well as the flanking
exons, which I called A23, for ARGLU1 exons2-3 (Figure 2.5). When transfected into HEK-293T
cells, this vector is spliced similarly to the endogenous ARGLU1, with the retained intron mRNA
representing approximately half of the mRNA derived from the reporter (Figure 2.6 and 2.7).
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To test the role of the UCE in intron retention, I created a number of deletions in the
splicing reporter vector. I created a large deletion of 504 bp, representing the sequence 95%
conserved with chicken. I also made a series of three smaller deletions of 168 bp that were
subdeletions of this large 504 bp deletion. A control deletion was also made of the same size in a
non-conserved region of the intron. Using RNase protection assays, I observed that the wild type
and control deletion reporter vector, as well as 168 bp deletion 1, showed mostly retained intron
RNA when transfected (Figure 2.6). However, the 504 bp UCE deletion as well as 168 bp deletions
2 and 3 caused a dramatic increase in splicing of exons 2 and 3 (Figures 2.6 and 2.7).
To determine specific sequences regulating ARGLU1 alternative splicing, a series of 25
bp deletions were created spanning the 168 bp deletions 2 and 3 (Figure 2.5), which had previously
been shown to contain regulatory sequences. To compare spliced and retained isoforms of the
splicing reporter, I designed a set of primers for competitive RT-PCR, in which I used a forward
and reverse primer annealed to transcribed plasmid specific sequences flanking the insert along
with a primer within the retained intron (Figure 2.5). Deletions of sequences upstream and
including the skipped alternative exon were found to increase splicing of exons 2 and 3 (Figure
2.6 and Figure 2.7). It should be noted that deletion 168-3, located downstream of the annotated
alternative exon, caused increased splicing with a shifted band, indicating the inclusion of the
alternative exon (Figure 2.7). Intriguingly, deletion of sequences downstream of the skipped exon,
including 168-3 and 25 bp deletions 9-11, increased the inclusion of the normally skipped
alternative exon, with usage of different 5’-splice sites on the now included exon depending on the
deletion (Figure 2.7). The observation that different 5’-splice sites could be used following
deletion of these sequences downstream of the alternative exon indicated that there might be
alternative 5’-splice sites competing within this region as well as important regulatory sequences.
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Figure 2.5 Diagram of the A23 splicing reporter vector. A PCR-derived fragment that includes
Exon2-intron 2- Exon3 was cloned into the pcDNA3 plasmid, and it was named A23, after
ARGLU1 exons2-3. I then confirmed that this splicing reporter recapitulated the splicing of the
endogenous mRNA, generating both a spliced and retained intron mRNA. I then generated a
number of deletion mutants of this plasmid, including a 504 bp deletion of the sequence 95%
conserved between human and chicken, as well as a 500 bp control deletion in a non-conserved
region of the intron. I then made three 168 bp deletions to subdivide the 504 bp deletion. These
were tested by RPA (Figure 2.6), and it was determined that only deletions 168-2 and 168-3 altered
splicing. Finally, I made a series of 25 bp deletions that spanned deletions 168-2 and 168-3.
Primers used in subsequent RT-PCR assays are indicated as labeled arrows.
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Figure 2.6 RNase Protection Assay indicates that elements within the UCE inhibit splicing
of ARLGU1 exons 2 and 3. RNA from cells transfected with the A23 splice reporter vector or
the derivatives noted was hybridized with a body labeled probe that annealed to exon 3 into the
retained intron. Splicing of the reporter resulted in the lower band. This figure represents two
replicates.
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Figure 2.7 Competitive RT-PCR shows that specific elements within the ARGLU1 UCE
regulate intron retention, Exon2-3 splicing, and alternative exon inclusion. The A23 splicing
reporter plasmid as well as the deletion mutants were transfected into HEK-293 cells. RNA was
harvested and used for competitive RT-PCR. Primers for RT-PCR are indicated in Figure 2.5.
The bands produced from the primer sets are indicated on the right.
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2.2.4 Analysis of putative splice sites bounding the alternative exon:
To test what, if any, role the splice sites bounding the UCE alternative exon and the possible
5’-splice sites downstream of this alternative exon play, I mutated these splice sites individually
and in combination (Figure 2.8A). Mutation of the annotated 3’ splice site of the alternative exon
leads to decreased intron retention and increased splicing of Exon 2-Exon 3 (Figure 2.8B).
Furthermore, plasmids with a mutation of this 3’ splice site completely lacked splicing inclusion
of the alternative exon (Figure 2.8B). Mutating the annotated 5’-splice site of the UCE exon did
not drastically change the ratio of spliced to retained intron 2. Interestingly though, it did cause
an increase in alternative exon inclusion; however the included exon was larger, indicating the
usage of a different 5’-splice site downstream of the normal splice site (Figure 2.8B).
I also created mutations in six possible 5’-splice sites downstream (containing either a GT
or GC dinucleotide), to determine which, if any, of these sequences might regulate inclusion of the
UCE exon (Figure 2.8A). I found that mutation of putative splice sites 2-4 did not alter the ratio
of intron retention to spliced product. These mutations did cause a change in the inclusion of the
alternative exon, which was the larger of the two noted bands (Figure 2.8B). Interestingly,
mutation of putative splice sites 5 and 6 did alter the ratio of retained and spliced reporter, causing
an increase in splicing. Furthermore, these mutations caused a difference in splicing of the
alternative exon as well, with exclusive inclusion of the smaller band (Figure 2.8B).

By

sequencing RT-PCR products from cells transfected with these plasmids, I determined that
mutation of SS5 and SS6 caused exclusive use of the annotated 5’-splice site. Additionally, Sanger
sequencing of the products from SS3 and SS4 indicated that the upper band corresponds to SS5
(Data not shown). Analysis for the predicted 5’-splice site using a variety of computational models
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(Yeo and Burge, 2004) indicates that the annotated 5’-splice site is actually weaker compared to
other 5’-splice sites analyzed, especially splice sites 5 and 6 (See Table 2.1).
To further analyze the role of the splice sites flanking the retained intron and skipped exon,
I improved the splice sites to match strong consensus 5’- or 3’-splice sites (Figure 2.9A). I found
that improvement of the 5’-splice site of exon 2 or the 3’-splice site of exon 3 did not appreciably
increase the ratio of spliced to retained product (Figure 2.9B). However, mutation of the 3’ splice
site of the alternative exon dramatically increased the inclusion of the alternative exon, as indicated
by a shift in the spliced band obtained by RT-PCR (Figure 2.9B). As seen in previous experiments,
there seem to be two shifted bands (Figure 2.8B), indicating that two possible 5’-splice sites can
be used upon inclusion of the alternative exon. Mutation of the annotated 5’-splice site of the
alternative exon to a consensus 5’-splice site also leads to increased inclusion of this alternative
exon by RT-PCR (Figure 2.9B). Interestingly, there is only one band in this situation, which
indicates usage of only one 5’-splice site, which was confirmed by Sanger sequencing to be the
improved alternative 5’-splice site.
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Figure 2.8 Mutagenesis of 3’- and putative 5’-splice sites downstream of the alternative exon
modulates both intron retention and alternative exon inclusion. A. Splice site mutation
derivatives of the A23 splicing reporter are detailed. The 3’ splice site of the alternative exon is
noted in green, and 5’-splice sites are noted in red. The 3’ splice site was mutated. 5’-splice sites
were mutated from GU to CA. B. RT-PCR was performed from HEK-293 cells transfected with
the noted splicing reporter mutant.

Two sets of PCR were performed, one with primers

vecF+vecR+retR to assess splicing vs intron retention, and a second with altF+vecR to assess the
5’-splice site used upon alternative exon inclusion. At the bottom is the sequence of the region
surrounding the alternative exon.
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Figure 2.9 Improvement of the alternative exons, but not the constitutive exons, changes
intron retention and alternative exon inclusion. A. Mutations were made in the A23 splicing
reporter to improve the splice sites of the constitutive exons 2 and 3, or the splice sites flanking
the alternative exon. Below the diagram is the specific sequence that was mutated. The top line
is the endogenous sequence, and the bottom line is the mutant sequence. B. RT-PCR was
performed from HEK-293 cells transfected with the noted splicing reporter plasmid. Primers are
indicated in Figure 2.9A and the bands are indicated on the right.
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Splice site

9-mer sequence

MAXENT:

MDD:

MM:

WMM:

Alt 5'

aca|GTaaat

1.91

2.98

3.33

3.74

SS1

aat|GCtgat

-20.87

-14.68

-17.9

-9.94

SS2

gga|GTatag

-7.36

1.08

0.86

-0.91

SS3

tag|GTaaag

6.93

11.08

5.49

6.65

SS4

tac|GTaggt

4.81

9.18

4.92

5.81

SS5

tag|GTatac

4.69

8.18

3.68

3.41

SS6

ttg|GTgaga

6.29

11.68

6.58

6.27

Table 2.1 Analysis of 5’-splice site strength using various models. Predictions were made
using the MAXENT tool (Yeo and Burge, 2004).
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2.2.5 Modification of the endogenous ARGLU1 UCE disrupts intron retention:
I next sought to validate the ability of mutations and deletions within the UCE to cause
changes in splicing. To accomplish this I used the Cas9/CRISPR system (Ran et al., 2013) to
generate random mutations by non-homologous end joining. I designed two different guide RNAs
targeting the UCE (appendix A). I inserted these guides into a plasmid co-expressing the sgRNA
as well as Cas9 fused to GFP by a self-cleaving PP2A polypeptide (Ran et al., 2013). These
plasmids were transfected into HEK-293 Flp-In T-Rex cells. I then sorted single cells expressing
GFP into 96 well plates and allowed them to grow until the cells formed colonies. I was able to
isolate a number of clones with heterozygous or compound heterozygous insertions and deletions
within the UCE (data not shown), all of which demonstrated increased splicing and decreased
levels of ARGLU1 intron retention compared with wild-type cells (Figure 2.10). Clone 4 showed
the largest increase in the ratio of spliced/retained intron, and contained a homozygous single
nucleotide insertion within the alternative skipped exon (Figure 2.10). However, other interesting
clones were also obtained. For example, clone 14 contained a single nucleotide homozygous
deletion within the alternative exon that caused inclusion of this alternative to be frame
maintaining, thus stabilizing mRNAs that contained the alternative exon (Figure 2.10). Finally,
clone 3 had a large heterozygous insertion within the alternative exon that caused increased
inclusion of the alternative exon (Figure 2.10.
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Figure 2.10 Disruption of the UCE at the endogenous chromosomal locus disrupts intron
retention vs splicing. A. Primers used for RT-PCR. B. RT-PCR of RNA from clonal HEK-293
cell lines in which Cas9/CRISPR was used to target double stranded breaks to the alternative exon
in the UCE. A number of clones were recovered that had a mixture of insertions and deletions.
Clone 4 contains a homozygous single nucleotide insertion in the UCE that dramatically increased
splicing and decreased intron retention. Clone 3 included a large insertion in the UCE that
increases inclusion of the alternative exon including the insertion (noted by a *). Clone 14 contains
a single nucleotide deletion that causes the alternative exon to be in frame, causing transcripts
including the alternative exon to be stabilized. The included alternative exon is noted by a †). C.
Chromatograph from Clone 4 indicating a single nucleotide insertion in the alternative exon in the
UCE.
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2.2.6 ARGLU1 intron 2 is sufficient to induce intron retention in an exogenous context
Previous experiments have shown that the UCE in the ARGLU1 intron 2 is necessary for
intron retention or inhibition of splicing. However, we next wanted to ask whether the ARGLU1
intron could cause splicing inhibition in an exogenous context. To that end, I cloned the ARLGU1
intron 2 into the pzw1 vector in either the forward or reverse direction. The pzw1 vector consists
of an EGFP cDNA with an intron containing a multiple cloning site in the middle of the GFP
critical fluorescent site. The intron is inefficiently spliced, but the addition of sequences into the
exon has been used to determine sequences that modify exon splicing (Wang et al., 2004). I found
that the forward ARGLU1 insert, but not the reverse insert, was sufficient to generate a band
consistent with the retained intron. However, the majority of the RT-PCR product indicated
splicing, possibly because the 5’- and 3’-splice sites in the vector are quite strong.
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Figure 2.11 ARGLU1 intron 2 is sufficient to induce intron retention in an exogenous context.
The pzw1 vector contains an intron with an MCS in the middle of EGFP. ARGLU1 intron 2 was
inserted into this MCS in either a forward (intF) or reverse (intR) direction (i.e. the reverse
compliment as a size-matched control). These plasmids were transfected into HEK-293 cells, and
RNA was harvested 24 hours later. RT-PCR using competitive PCR with the primers indicated
can detect a band produced by splicing as well as one consistent with intron retention.
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2.3 Conclusion:
I have identified ARGLU1 as a transcript that has a number of interesting characteristics.
First, it has a retained intron, a form of alternative splicing relatively rare and poorly understood
in mammals. Second, the ARGLU1 isoform containing the retained intron is localized exclusively
in the nucleus. These two characteristics have recently been used to define a class of mRNAs
labeled ‘detained introns’ (Boutz et al., 2015). That study identified ARLGU1 as a detained intron
in both human and mouse cells (Boutz et al., 2015). I have shown through multiple methods,
including RNA-seq, RT-PCR and northern blot that the retained intron ARGLU1 transcript is
abundant and exclusively nuclear. Additionally, it does not seem to be sensitive to NMD, as
treatment with emetine did not increase the abundance of the retained intron isoform. Insensitivity
to NMD was another characteristic used by Boutz et al. (Boutz et al., 2015) to functionally separate
‘detained introns’ from transcripts with retained introns that were exported from the nucleus and
degraded by NMD. The third intriguing characteristic of ARGLU1 is that there is a UCE
associated with the retained intron. As mentioned previously, the presence of UCEs has been
linked to alternative splicing and homeostatic regulation of SR proteins (Lareau et al., 2007; Ni et
al., 2007; Sun et al., 2010; Sureau et al., 2001).
In this chapter I have defined many of the cis-regulatory elements that control alternative
splicing of ARGLU1. In line with previous reports that UCEs are associated with alternative
splicing linked to NMD (Lareau et al., 2007; Ni et al., 2007), I have shown that there is an NMD
sensitive alternative exon that lies completely within the ARLGU1 UCE. However, unlike
previous studies of these UCE-linked alternative splicing events, I have experimentally tested the
role of sequences within the UCE to show this sequence is both necessary and sufficient to induce
intron retention.
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The presence of the alternative exon within the retained intron of ARGLU1 seems to be
central to the regulation of intron retention. Deletion of sequences that overlap the alternative exon
cause a dramatic decrease in the level of intron retention relative to splicing of exon2-exon3.
Mutation of the 3’-splice site of the alternative exon causes a dramatic increase in exon2-exon3
splicing and a decrease in intron retention. Furthermore, deletion or mutation of sequences
downstream of the alternative exon also seem to regulate splicing of exon2-exon3. In particular,
mutation of two 5’ss-like sequences downstream of the alternative exon (SS5/SS6) seem to
dramatically increase splicing exon2-exon3. Conversely, mutation of two different 5’ss-like
sequences in downstream of the alternative exon cause increased usage of the alternative exon, but
changes the 5’ss of the alterative exon to SS5.
On the other hand, improving the annotated splice sites flanking the alternative exon causes
a marked increase in the usage of the alternative exon. In particular, mutation of the 3’-splice site
and addition of upstream pyrimidine caused a dramatic increase in the alternative exon usage,
albeit with evidence of multiple 5’-splice sites, in line with previous results. Interestingly,
improvement of the annotated 5’-splice site alone also increased inclusion of the alternative exon,
but with usage of that splice site alone.
These data suggest a complicated cis-regulatory environment centered on the presence of
an alternative exon. Based on the fact that improvement of either the 3’ or 5’-splice site of the
alternative exon shifts splicing almost exclusively to the inclusion of that exon, I propose that there
is poor exon definition of the alternative exon.

However, the mutagenesis of sequences

downstream of the alternative exon indicate that there are other regulatory elements that seem to
function as both intronic and exonic splice suppressors. The sequences at SS3 and SS4 seem to
increase usage of the SS5 putative 5’ss at the expense of the annotated 5’-splice site, indicating
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that these sequences may act as intronic splice silencers. Conversely, mutation of SS5 and SS6
sequences cause the sole use of the annotated 5’ss of the alternative exon, and also increase exon2exon3 splicing. This indicates that the presence of at least one competing 5’ss downstream of the
alternative exon is important for regulation of intron retention versus exon2-exon3 splicing. I
therefore suggest that the combination of weak splice sites flanking the alternative exon as well as
multiple putative 5’-splice sites downstream of this alternative exon causes poor exon definition,
but is sufficient to act as a decoy for productive splicing of the upstream and downstream exons.
This decoy exon may then form splicing complexes that are not able to be completed, and thus
lead to intron retention.
This model seems to be in line with a previously proposed model of intron retention
(Sakabe and de Souza, 2007). The improper exon definition model of intron retention is based on
failure of complete exon definition. The exons flanking the retained intron are defined by
interactions of cis- and trans-factors. However, after this exon definition step, these defined exons
go on to associate and remove the intron, or fail to associate and thus retain the intron. This failure
would be presumed to occur as a result of the spliceosome failing to transition from complex E to
A, indicating that not all of the important exonic sites were recognized, or from a failure in
transition from complex A to B, indicating that the 5’-and 3’ splice sites were not brought together.
A number of trans-factors have been shown to inhibit the assembly of the E complex, including
hnRNPA1 (Yu et al., 2008). Interestingly, SRSF7, which normally stimulates exon inclusion, can
play an inhibitory role if it binds intronic sequences proximal to exons, and was shown to inhibit
progression past the spliceosomal E complex (Erkelenz et al., 2013). Other proteins have been
shown to prevent the rearrangement of the spliceosome beyond the A complex, including PTB
(Sharma et al., 2008, 2011).
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2.4 Materials and Methods
Cell Culture
HEK-293 cells were maintained in DMEM supplemented with 10% fetal bovine serum and 100
U/mL Penicillin-Streptomycin. Cells were grown at 37°C, in an environment maintained at 5%
CO2.
Nuclear/Cyotplasmic Fractionation
Nuclear/Cyotplasmic fractionation was carried out as in (Chen et al., 2008) with some
modifications. 10 cm dishes of cells were washed twice with ice-cold PBS. These cells were then
harvested by scraping in ice-cold PBS and pelleted by centrifugation at 1000 x g for 5 minutes at
4°C. Cells were then gently resuspended in 250 uL of lysis buffer A (10 mM Tris (pH 8.0), 140
mM NaCl, 1.5 mM MgCl2, 0.5% Igepal, 2 mM vanadyl ribonucleoside complex (VRC;
Invitrogen)) and incubated on ice for 5 minutes. During this incubation 1/10th of the total cell
lysate was retained for western blotting and 1/5th of the whole cell lysate was added to 1 mL of
Trizol reagent. The rest of the lysate was centrifuged for 3 minutes at 4°C to pellet the nuclei. The
supernatant was reserved as the cytoplasmic fraction, and was spun a second time to remove any
remaining nuclei. 1/5th of the cytoplasmic fraction was then used for western blot, while the
remaining fraction was added to 1 mL of Trizol reagent. The remaining nuclear pellet was washed
2X with 300 uL lysis buffer A, then the nuclei were resuspended in 100 uL of lysis buffer A, 1/5th
of the nuclear lysate was used for western blot and the remaining nuclear fraction was added to 1
mL of Trizol reagent.
Northern Blotting
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10 ug of RNA was used for loading onto a 1% agarose in sodium phosphate buffer. RNAs were
resuspended in a RNA gel loading buffer containing glyoxal, bromophenol blue and xylene cyanol.
RNAs were denatured at 75 C for 3 minutes, then loaded into the gel. The RNAs were resolved
at 90 volts for 1 hour. RNA was then transferred to positively charged nylon membrane using
capillary transfer in 20X SSC for 4 hours. After transfer, the membrane was crosslinked to the
membrane using 1200 mJ UV 285 nm irradiation. The membrane was then blocked using Ambion
Northern Max hybridization buffer. The membrane was then hybridized over night with an RNA
probe against a region common to both the sliced and intron retained isoforms that was internally
labeled with biotin. The membrane was then washed first with low stringency wash buffer 1X,
and high stringency buffer 2X. The probes were detected with alkaline phosphatase conjugated
streptavidin and illuminated with CDP-star chemiluminescent reagent.
Plasmids
The A23 plasmid was created using a pcDNA3 vector backbone. A PCR fragment consisting of
the genomic region spanning ARLGU1 exon 2 to exon 3, including the intron, was TA cloned into
the TOPO 2.1 vector, thus the name A23. A clone was selected that did not show any mutations
within the UCE or within 300 bases of either exon. The A23 fragment was excised from the TOPO
2.1 vector using EcoRI, which cleaves on both sides of the fragment, and cloned into the pcDNA3
expression vector also cut with EcoRI. This resulted in both forward and reverse inserts into the
pcDNA3 vector. A number of clones were obtained for each direction, and clones were again
screened with Sanger sequencing to ensure no mutations in the UCE or within 300 bases of either
exon. The forward pcDNA A23 clone #3 was then used for future experiments. All other A23
mutants were derivatives of this initial plasmid.
Mutagenesis
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Mutagenesis was carried out using the Q5 mutagenesis protocol. Briefly, PCR of circular plasmids
was carried out with non-overlapping opposing forward and reverse primers that together
contained the mutation or flanked the area to be deleted. The PCR products were then treated with
a mixture of T4 PNK, DpnI nuclease, and T4 DNA ligase. This mixture was then transformed into
DH5α E. coli. Mutations were confirmed by Sanger sequencing. Primers used for each mutagnesis
are listed in appendix A.
RNase Protection Assay
RPAs were carried out using the Ambion RPA III kit according to the manufacturer’s instructions.
Labeled RNA probes were generated from an A23 plasmid with a reverse insert using the plasmid
T7 promoter and internally labeled with Biotin-UTP. The RNA probes were then denatured and
hybridized overnight to RNA from cells transfected with the A23 reporter plasmids. Nonhybridizes RNA was then digested with a mixture of RNase A and T1. The RNAs were then
purified and resolved on a 5% TBE-urea polyacrylamide gel. The protected fragments were
transferred to positively charged nylon membrane, and probed with an alkaline phosphatase
conjugated streptavidin. The chemiluminescent reagent CDP-star was used to expose the bands.
The membrane was then imaged on a Kodak Image Station machine.
Preparation of RNA
RNA was prepared by lysing cells in an appropriate volume of Trizol (Life Tech). Chloroform
was added, mixed vigorously, and incubated on ice for 5 minutes. These samples were centrifuged
at maximum speed for 15 minutes. The aqueous phase was then recovered and precipitated by the
addition of equal volume 100% isopropanol with glycoblue carrier added. The RNA pellet was
then washed 1X with 75% ethanol and resuspended in an appropriate volume of RNase free water.
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RNA concentration was assessed using Absorbance at 280 on a nanodrop spectrophotometer. 5
ug of RNA was treated with Ambion Turbo-DNA free DNase I reagent, and collected into fresh
tube following treatment with the Ambion DNase I inactivation reagent.
RT-PCR
Reverse transcription was carried out on DNase I treated RNA using the Protoscript II cDNA
synthesis kit using random primers (New England Biolabs). PCR was then carried out using
OneTaq quick load master mix (NEB) with the primers indicated for each experiment. RTsamples were also used as a control for all PCR sample to test for residual DNA. Primers can be
found in Appendix A.
Cas9/CRISPR
I used the px458 plasmid (Ran et al., 2013) in order to generate site directed double stranded breaks
in the UCE. This plasmid contains the Cas9 nuclease fused to GFP with a self-cleaving PP2A
peptide, causing transfected cells to fluoresce when Cas9 is expressed. I cloned 2 separate guide
RNAs into the expression plasmid, and transfected them into HEK-293 Flp-In TRex cells. After
24 hours, cells were FACS sorted and cells were plated into individual wells 96 well plates. After
growing cells to obtain clonal colonies, cells were screened with PCR and sequencing of the
genomic region surrounding the targeted sites. RT-PCR was carried out using primers in exon2F
and exon3R, listed in appendix A.
Western blotting
Cells were lysed for 30 minutes in ice cold RIPA buffer supplemented with protease inhibitors and
benzonase. Protein was quantified using the BioRad Cell lysates were then mixed with 2X
Laemmli’s SDS loading buffer with 10 mM DTT. 30 µg of protein was loaded into SDS-PAGE
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gels and resolved at 100V. Transfer to nitrocellulose membrane was carried out in Tris-glycine
buffer with 10% methanol at 4°C at 240 mA for 2 hour. Membranes were blocked with Licor
blocking buffer for 1 hr at room temperature. Blots were then incubated overnight at 4°C with
primary antibody diluted (TBP 1:1000, GAPDH 1:2000) in Licor blocking buffer supplemented
with 0.1% tween-20. Membrane was then washed with TBS-0.1% tween 3 times for five minutes.
Appropriate florescent labeled secondary antibodies diluted in Licor blocking buffer with 0.1%
tween and 0.01% SDS were incubated with the membrane for 45 minutes at room temperature
with rocking. Membrane was then washed with TBS-0.1% tween 3 times for five minutes.
Membranes were imaged on the Licor Odyssey system.
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Chapter 3
ARGLU1 Protein Regulates the Splicing of its own mRNA
3.1 Introduction
This chapter will focus on the homeostatic regulation of ARGLU1 mRNA splicing. As
described in the previous chapter, an ultraconserved element (UCE) is associated with the complex
alternative splicing of ARGLU1 through the regulation of an alternatively spliced in exon as well
as a retained intron.
Previous studies have indicated that UCEs and other highly conserved elements, are often
associated with alternative splicing events (Baek and Green, 2005; Lareau et al., 2007; Ni et al.,
2007). Interestingly, SR proteins, a class of proteins known to promote RNA splicing and
implicated in alternative splicing, are enriched for highly conserved sequences around exons that
are alternatively spliced. A number of studies have indicated that SR proteins can cause feedback
loops that act to regulate splicing of their own mRNAs, and consequently protein levels, including
SRSF1 (Sun et al., 2010) and SRSF2 (Sureau et al., 2001).
These highly-conserved element-associated alternative splicing events are often linked
with a process known as nonsense-mediated decay (NMD). NMD is a cellular quality control
mechanism that functions to degrade mRNA transcripts containing aberrant premature termination
codons (PTCs). These PTCs are recognized by the presence of a complex known as the Exon
Junction Complex (EJC), which is a group of proteins deposited 24 bases upstream an exon-exon
junction (Le Hir et al., 2001; Shibuya et al., 2004). The EJC is important for nuclear export of
spliced RNAs (Le Hir et al., 2001; Schell et al., 2002) and translation (Nott et al., 2004). However
it also serves as a platform for the assembly of the NMD machinery. UPF1 is one of the major
components of the NMD pathway and is recruited to stop codongs along with another NMD factor,
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SMG1, and the release factors eRF1 and eRF3 (collectively known as the SURF complex)
(Kashima et al., 2006). If an exon junction complex is present more than approximately 50 bases
downstream of this stop codon, an interaction between the SURF complex and UPF2 in the EJC
will lead to phosphorylation of UPF1 (Chamieh et al., 2008), leading to recruitment of the
endonuclease SMG6 and consequently RNA degradation (Kervestin and Jacobson, 2012).
In this chapter, I will test the hypothesis that ARGLU1 protein has a regulatory role
on the splicing of its own mRNA. Based on previous findings that the highly conserved
sequences around the alternative exon are important for regulation of ARGLU1 spicing, I propose
that the ARGLU1 protein itself may function to regulate this splicing event.

To test this

hypothesis, I have designed a cell line that allows expression of ARGLU1 protein in a tetracyclineinducible manner. Using this system, I have assessed the impact of ARGLU1 overexpression on
the splicing of the endogenous ARLGU1 mRNA transcripts, causing a decrease in exon2-exon3
splicing and an increase in inclusion of the alternative exon that is subject to NMD. Conversely,
I will show that inhibition of protein synthesis is associated with splicing regulation opposite of
that seen with ARGLU1 overexpression.
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3.2 Results
3.2.1 ARGLU1 overexpression alters splicing of the A23 splicing reporter
I hypothesized that one role of the UCE in ARGLU1 splicing could be to regulate protein
expression levels through alternative splicing. This would suggest that ARGLU1 protein might
feedback to alter splicing of its own RNA. To test this hypothesis, I tested the effect of a plasmid
encoding an ARGLU1 cDNA on the splicing of the A23 splicing reporter vector (Figure 3.1A). I
mock-transfected, or co-transfected the ARGLU1 cDNA expressing plasmid with the WT A23
reporter, the control deletion A23 reporter, or the 504 bp deletion reporter (Figure 3.1B). Similar
to previous experiments, in cells not transfected with the ARGLU1 cDNA plasmid I saw that the
504 bp UCE deletion caused increased splicing of the reporter transcript compared with the WT
reporter, while the control deletion did not (Figure 3.1B). However, in cells transfected with the
ARGLU1 cDNA, the WT and control deletion reporter transcripts had a decreased ratio of
spliced/retained compared with the cells not transfected with the ARGLU1 cDNA plasmid (Figure
3.1B). The 504 bp UCE deletion reporter had an increased ratio of spliced/retained transcript, and
was not affected by the transfection of ARGLU1 cDNA (Figure 3.1B).
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Figure 3. 1 Transient transfection of ARGLU1 protein alters splicing of the A23 splicing
reporter. A. Diagram of the A23 splicing reporter vector with the 504 bp and control deletion
noted. Primers for 3.1B are noted B. The A23 WT, A23 504 bp deletion, or Control Deletion
splicing reporter plasmids were co-transfected with either a plasmid overexpressing ARGLU1
cDNA or empty vector. Splicing was assessed with the use of 3 primers, vecF, vecR, and RetR,
seen in Figure 3.1A.
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3.2.2 Inducible overexpression of ARGLU1 decreases endogenous ARGLU1 protein and
alters splicing of the endogenous ARGLU1 mRNA
To test whether this finding also held true for the endogenous transcript, I created a stable cell line
that overexpressed ARGLU1 in a tetracycline-inducible manner. Using the HEK-293 Flp-In TRex
cell line, I made cell lines expressing ARGLU1, ARGLU1 with a C-terminal HA tag, or the gene
chloramphenicol acetyltransferase (CAT) as a control (Figure 3.2). Induction of ARGLU1
overexpression for 24 hours with 1 µg/mL of tetracycline caused a dramatic overexpression of
ARGLU1 protein (Figure 3.3). Intriguingly, I found that overexpression of the HA-tagged version
of ARGLU1, which migrates slightly slower by SDS-PAGE, led to a dramatic decrease in the level
of the endogenous protein (Figure 3.3). This suggested to us that ARGLU1 protein leads to
feedback that maintains ARGLU1 protein levels. Based on previous findings, I hypothesized that
this could occur through regulation of alternative splicing. Indeed, quantitative RT-PCR analysis
of splicing of the endogenous transcript after 24 hours of induction indicated that there was a 6fold decrease in the fully spliced endogenous transcript, and 1.6-fold increase in the retained intron
transcript (Figure 3.4). These changes were also observed by semi-quantitative RT-PCR using
primers that captured both the spliced and retained transcripts (Figure 3.5).

Intriguingly,

overexpression of ARGLU1 caused not only an increase in intron retention and a decrease in the
spliced isoform, but also appeared to increase the inclusion of the alternative exon (Figure 3.4).
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Figure 3.2 293 Flp-In TRex inducible expression of ARGLU1. This is a representation of the
Flp-In T-Rex system (Life Technologies). The Flp-In component is created using the
pcDNA5/FRT/TO plasmid containing the gene of interest fused to a CMV promoter with two
tetracycline operator (TetO) sequences. The vector also has a FRT site adjacent to a hygromycin
resistance gene. This plasmid can be recombined at a single stably integrated FRT site, which then
drives the hygromycin resistance gene. There is a separate stably integrated component that
constitutively expresses the tetracycline repressor (TetR) and is under blastcidin selection. The
TetR gene will bind to TetO in the absence of tetracycline/doxacycline, repressing expression of
the gene of interest. Addition of tetracycline will cause a conformational change in the TetR,
releasing it from the TetO and allowing transcription of the gene of interest. I have made 3 stable
cell lines with this system, expressing ARGLU1 cDNA (ARGLU1-TO), ARGLU1-HA cDNA
(ARGLU1-HA-TO), and CAT cDNA (CAT-TO) as a control.
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Figure 3.3 ARGLU1 overexpression from the 293 Flp-In T-Rex derived cell lines. Cell lines
with inducible induction of either CAT (CAT-TO), HA tagged ARGLU1 cDNA (ARGLU1-HATO), or ARGLU1 cDNA (ARGLU1-TO) were either induced with 1 ug/ml tetracycline (+tet) or
mock treated (-tet) for 24 hours. Western blot was performed with antibodies against alpha-tubulin
as a loading control and ARGLU1. Note that the endogenous ARGLU1 band is not present
following ARGLU1-HA overexpression.
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Figure 3.4 ARGLU1 overexpression increases levels of retained intron mRNA and decreases
levels of spliced mRNA A. Primers used for RT-qPCR in B, as well as elsewhere. Ex2F+UTRR are used to measure ARLGU1 endogenous spliced mRNA, and ex2F+IntR are used to measure
ARGLU1 retained intron mRNA. B. RT-qPCR of the indicated HEK-293 Flp-In derived cell lines
(Control is CAT-TO) either induced 1 µg/ml tetracycline (+tet) or mock treated (-tet) for 24 hours.
mRNA levels are normalized to actin, and set relative to ARGLU1-TO –tet. Sample n=3, and
error bars represent SEM.
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Figure 3.5 Induced overexpression of ARLGU1 causes a dramatic shift in endogenous
ARGLU1 splicing A. Primers used for semi-quantitative RT-PCR. B. Semi-quantitative PCR was
performed on RNA from ARGLU1-TO cells either induced with 1 µg/ml tetracycline (+tet) or
mock treated (-tet) for 24 hours. RNA was then used for RT-PCR with a long extension time to
capture all potential spliced isoforms, including fully spliced, retained intron, and alternative exon
inclusion. Lanes 1 and 2 are replicates of mock treated cells. Lanes 3 and 4 are replicates of 1
ug/ml tetracycline treated cells.
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3.2.3 Changes in ARGLU1 splicing correspond closely with ARGLU1 protein levels
I next tested how quickly these splicing changes occurred in ARLGU1 following induced
overexpression of the ARGLU1-HA protein. Using an HA-tagged ARGLU1 construct allowed
me to assess and correlate ARGLU1 protein level in the cell with the splicing status of the
endogenous ARGLU1 mRNA. I found that following induction of ARLGU1-HA the endogenous
mRNA showed a significant decrease in the spliced isoform to approximately 35% of baseline
levels, with no change in the retained intron isoform (Figure 3.6A). This was seen as early as 2
hours after induction, when ARGLU1-HA levels were only 75% of endogenous levels, and total
ARGLU1 protein levels were approximately 1.8 times baseline (Figure 3.6B). With continued
expression of ARGLU1-HA, levels of the endogenous spliced ARGLU1 mRNA continued to
decrease, with a concomitant decrease in the endogenous protein (Figure 3.6A, B). This indicated
an inverse correlation between total ARGLU1 protein levels and the level of spliced ARGLU1
mRNA.
To test the hypothesis that ARGLU1 protein levels correlate with splicing of ARGLU1
mRNA, I used emetine to inhibit translation of new proteins. This led to rapid turnover of
ARGLU1, with a protein half-life of approximately 4 hours (Figure 3.7B). Using qRT-PCR to
determine the levels of the spliced and retained intron isoforms of ARGLU1, I saw a dramatic 2.7fold increase in the spliced product with a concurrent decrease in the retained intron isoform after
4 hours of treatment with emetine (Figure 3.7A). Taken together with the splicing changes seen
following overexpression of ARGLU1 protein, this suggests that ARGLU1 maintains homeostatic
control of its own protein level by regulating splicing of its ARGLU1 mRNA.
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Figure 3.6 ARGLU1-HA overexpression rapidly alters endogenous ARGLU1 splicing
A. RT-qPCR was performed using the primer sets detailed in figure 3.4A for the spliced and
retained intron isoforms. RNA was harvested from ARGLU1-HA-TO cells at 2,4, and 8 hours
following 1 µg/mL tetracycline induction, as well as from mock treated cells. For each time point
n=3 and error bars represent the SEM. B. Protein quantification of ARGLU1 and ARGLU1-HA
based on western blotting with an ARGLU1-antibody. Protein levels were normalized to tubulin
and set relative to the endogenous protein level at time 0. For each time point n=3 and error bars
represent the SEM.
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Figure 3.7 Inhibition of protein translation causes dramatic changes in ARLGU1 splicing
A. RT-qPCR was performed using the primer sets detailed in figure 3.4A for the spliced and
retained intron isoforms. RNA was harvested from HEK-293 cells at 1, 2, and 4 hours following
1 µg/mL tetracycline induction, as well as from mock treated cells. For each time point n=3 and
error bars represent the SEM. B. Protein quantification of ARGLU1 based on western blotting
with an ARGLU1-antibody. Protein levels were normalized to tubulin and set relative to the
endogenous protein level at time. For each time point n=3 and error bars represent the SEM.
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3.2.4 Inhibition of translation increases splicing of the protein coding isoform and stabilizes
an isoform containing the alternative exon:
Emetine has been used to study transcripts subject to degradation through NMD (Ni et al.,
2007; Noensie and Dietz, 2001), which is dependent on the pioneer round of translation. Given
that emetine leads to decreased levels of NMD, it would be expected that mRNA levels of NMD
targets should increase following treatment with emetine. I therefore performed semi-quantitative
PCR on cells treated with 50 µg/mL emetine or mock treated for 4 hours to assess the stability of
the spliced isoform, retained intron isoform, and alternative exon included isoform. Semiquantitative RT-PCR showed that the spliced isoform is increased (Figure 3.8B), in agreement
previous experiments shown in figure 3.7A. However, I found that the ARGLU1 retained intron
RNA levels decreased by 45% compared to untreated cells after 4 hours of treatment (Figure 3.7),
in contrast to the expected result if this transcript was subject to NMD. Furthermore, 4 hour
treatment with emetine caused stabilization of transcripts containing the alternative exon,
indicating that it is subject to NMD as predicted (Figure 3.8B).
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Figure 3.8 RT-PCR from cells treated with emetine shows stabilization of the alternative
exon containing RNA. A. Primers used for semi-quantitative RT-PCR. Primers ex2F and UTRR were used to look at the spliced mRNA. Primers UTR-R and altF were used to assess alternative
exon inclusion, and also captured the retained intron isoform. B. RT-PCR was performed from
cells treated with 50 µg/mL emetine (4 Hr emetine) or mock treated (-emetine) for 4 hours.
ARGLU1 spliced isoform is seen in the top panel. The retained intron and alternative exon
inclusion isoforms are seen in the middle panels, and actin is seen in the bottom panel. Lanes 1
and 2 are replicates of mock treatment and lanes 3 and 4 are replicates of emetine treatment.
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3.3 Conclusion
In this chapter I have addressed the role of ARGLU1 protein in the regulation of its own
splicing. As mentioned previously, splicing regulation takes place through cis/trans interactions.
In the previous chapter I have described the role of a cis element that regulates splicing of
ARGLU1. However, the trans-regulatory factors involved in this alternative splicing were not
clear. I developed a hypothesis based on different lines of evidence. First, ARGLU1 contains an
N-terminal domain that contains a number of SR dipeptides, an essential motif in SR and SR-like
proteins. Second, ARGLU1 physically interacts with (Hegele et al., 2012), and is phosphorylated
by (Varjosalo et al., 2013), SRPK1 and SRPK2, kinases that are known to regulate the activity of
the SR splicing factor proteins. Third, as demonstrated in the previous chapter, ARGLU1 has a
UCE that is associated with the regulated inclusion of an alternative exon predicted to lead to
NMD, a characteristic shared by many splicing factors (Lareau et al., 2007; Ni et al., 2007).
Finally, a number of SR proteins have been shown to feedback and regulate the splicing of their
own mRNAs to increase UCE associated exons containing PTCs that lead to degradation through
NMD (Sun et al., 2010; Sureau et al., 2001). Based on these data, I formed the hypothesis that
ARGLU1 may function as a regulator of splicing, and feedback to alter the splicing of its own
mRNA.
To test this hypothesis, I used an inducible system to overexpress ARGLU1 cDNA to
determine the impact of the ARGLU1 protein on splicing of the endogenous mRNA. Using this
system I have shown that, in agreement with my hypothesis, ARGLU1 overexpression
dramatically altered the splicing of the endogenous by decreasing the spliced mRNA expected to
code for the protein, increasing the retained intron isoform, as well as increasing inclusion of the
alternative exon that leads to degradation through NMD.
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3.4 Materials and Methods
Cell Culture
HEK 293-Flp-In TRex cells were maintained in DMEM with 10% FBS and 100 U/mL PenicillinStreptomycin. Cells in which the pcDNA5/FRT vector had been integrated were additionally
maintained in media supplemented with 15 ug/mL Blastcidin and 150 ug/mL Hygromycin B.
Induction of protein expression was performed by supplementing DMEM/Blast/Hygromycin
media with 1 ug/mL tetracycline for the times indicated in the text.
Plasmids
A cDNA for ARGLU1 was cloned into the pcDNA3 expression vector using primers detailed in
appendix A. This plasmid was used for the initial experiments for co-transfection with the A23
reporter plasmids, detailed in chapter 2. A C-terminal HA tag was added to the pcDNA3-ARGLU1
clone using Q5 site directed mutagenesis using primers found in appendix A. The ARGLU1 and
ARGLU1-HA cDNA fragments were then cloned into the MCS of the pcDNA5/FRT/TO vector
to generate pcDNA5/FRT/ARGLU1-TO and pcDNA5/FRT/ARGLU1-HA-TO plasmids. These
plasmids, as well as the pcDNA5/FRT/CAT-TO plasmids, were individually transfected into
HEK-293 Flp-In TRex cells along with the poG44 plasmid, which expressed FLP recombinase, to
mediate stable integration into the genomic FRT site. These cells were then selected as noted
above.
Emetine treatment
Cells were switched to DMEM 10% FBS supplemented with 50 ug/mL emetine for the time
indicated in the text. Mock treated cells received fresh media with no emetine.

72

Western blotting
Cells were lysed for 30 minutes in ice cold RIPA buffer supplemented with protease inhibitors and
benzonase. Protein was quantified using the BioRad protein quantification kit.
Cell lysates were then mixed with 2X Laemmli’s SDS loading buffer with 10 mM DTT. 30 µg of
protein was loaded into SDS-PAGE gels and resolved at 100V. Transfer to nitrocellulose
membrane was carried out in Tris-glycine buffer with 10% methanol at 4°C at 240 mA for 2 hour.
Membranes were blocked with Licor blocking buffer for 1 hr at room temperature. Blots were
then incubated overnight at 4°C with primary antibody diluted (ARGLU1 1:1000, Tubulin 1:1000)
in Licor blocking buffer supplemented with 0.1% tween-20. Membrane was then washed with
TBS-0.1% tween 3 times for five minutes. Appropriate florescent labeled secondary antibodies
diluted in Licor blocking buffer with 0.1% tween and 0.01% SDS were incubated with the
membrane for 45 minutes at room temperature with rocking. Membrane was then washed with
TBS-0.1% tween 3 times for five minutes. Membranes were imaged on the Licor Odyssey system.
Preparation of RNA
RNA was prepared by lysing cells in an appropriate volume of Trizol (Life Tech). Chloroform
was added, mixed vigorously, and incubated on ice for 5 minutes. These samples were centrifuged
at maximum speed for 15 minutes. The aqueous phase was then mixed with 70% ethanol and
processed with the Purelink RNA mini kit according to the manufacturer’s instructions. RNAs
were treated with Purelink On-column DNase I.
Absorbance at 280 on a nanodrop spectrophotometer.
RT-PCR and RT-qPCR
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RNA concentration was assessed using

RT was performed on DNase I treated RNA using the Protoscript II cDNA synthesis kit (NEB)
with random primers. Semi-quantitative RT-PCR was carried out using OneTaq 2X mastermix
(NEB) according to the manufacturer’s instructions. RT-PCR products were resolved in 2%
agarose TAE gels stained with ethidium bromide. RT-qPCR was carried out using iTaq Universal
SYBR Green Supermix on the CFX96 qPCR platform. Primers used in RT-PCR and RT-qPCR
are listed in appendix A.
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Chapter 4
ARGLU1 Overexpression Alters the Expression Level and Alternative Splicing of a Subset
of Genes
4.1 Introduction
In the previous chapter I have shown evidence that ARGLU1 protein levels are controlled
through a negative feedback loop, where high levels of ARGLU1 protein induce complex
alternative splicing of the ARGLU1 transcript that ultimately results in lower levels of ARGLU1
protein. Overexpression of ARGLU1 increases the inclusion of an alternative exon that appears
to lead to NMD degradation through the inclusion of a premature termination codon, increases
intron retention of a transcript that is detained in the nucleus, while at the same time decreasing
levels of the mature transcript that codes for the ARGLU1 protein. Additionally, ARGLU1 has
been found to physically associate with a number of proteins involved in splicing, including in
affinity purification of the spliceosome (Behzadnia et al., 2007; Bessonov et al., 2008; Hegele et
al., 2012; Varjosalo et al., 2013). Taken together, these findings raise the question of whether
ARGLU1 can regulate the splicing of other RNAs when overexpressed.
ARGLU1 protein has been shown to interact with MED1, a component of the mediator
complex to potentiate a transcriptional and cellular response to estrogen in this context (Zhang et
al., 2011). Mediator is a large, multi-subunit complex that brings together transcription factors
and the core RNA pol II machinery, allowing for licensing of transcription. MED1 in particular
is known to be recruited to enhancer sequences bound by nuclear receptors and potentiate
transcriptional activation of regulated genes. This suggests an alternative role for ARGLU1 in
transcriptional regulation.
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In this chapter I will address the role of ARGLU1 protein in regulating transcription levels
and alternative splicing in a transcriptome-wide manner. Based on the two probable functions for
ARGLU1 suggested by previous studies, transcriptional regulation and the splicing machinery, it
seems likely that ARGLU1 will play a role in RNA transcription or processing.
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4.2 Results
4.2.1 RNA-Seq
To assess the role of ARGLU1 protein overexpression on the transcriptome of HEK 293
cells, I employed a previously described system to induce the overexpression of ARGLU1 in
response to tetracycline. This system uses a tetracycline repressor to inhibit transcription of an
ARGLU1 cDNA, which is released with the addition of tetracycline. Therefore, this system could
be used to compare the mRNA compliment from cells overexpressing ARGLU1 against isogenic
cells that had not been induced. Furthermore, to control for the effect of tetracycline, I created cell
lines to express chloramphenicol acetyltransferase (CAT) following addition of tetracycline.
There are multiple control samples in this experimental setup. The main comparisons will
be made against the ARGLU1 +Tet group, which is the ARGLU1 inducible cell line treated with
tetracycline, which serves as the main control. The other control groups at the CAT +Tet group
and the CAT –Tet, which are the CAT inducible cell line treated with or without tetracycline,
respectively. In order to determine differences attributable to overexpression of ARGLU1, rather
than tetracycline or CAT expression, I have required that differences recovered from informatics
analysis are significant in either all three control samples compared with ARGLU1 +Tet, or at least
significantly different in both the CAT +Tet and ARGLU1 –Tet groups.
I used two different conditions treatment conditions for both the ARGLU1 and CAT
inducible cell lines. In duplicate for each condition, cells were treated with 1 µg/mL tetracycline,
or mock treated, for 24 hours. During cell harvesting, half the cells were used to create a whole
cell protein lysate, and the other half were treated with Trizol and processed using the Trulink
RNA mini kit to extract RNA for RNA-seq and other experiments. The protein extracts were used
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to assess the expression level of ARGLU1 in all samples (Figure 4.1). RNA from each sample
was analyzed by the Tapestation instrument using the RNA Screentape (Figure 4.2A). After
confirming that the RNA Integrity Number equivalent (RINe) (Schroeder et al., 2006) indicated
the RNA was of high quality, it was used to generate a stranded cDNA library appropriate for
sequencing on an Illumina platform using the Illumina Stranded mRNA TruSeq protocol. The
libraries were run on a high sensitivity DNA screentape (Figure 4.2B) to determine the average
size distribution of the libraries for molarity calculations, and as a check for aberrant products
following PCR amplification. These libraries were then sequenced with 2x76 bp reads on the
Illumina NextSeq platform.

78

Figure 4.1 Western blot of cell extracts from the cells used for RNA-seq experiments.
Western blotting was carried out on whole cell extracts from the samples used for RNA-Seq.
Tubulin was used as a loading control. The cell lines are indicated at the bottom, and treatment
with 1 ug/mL tetracycline or mock treatment is indicated below the individual samples.
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Figure 4.2 Quality control steps for RNA integrity and library size for RNA-seq libraries.
A. RNA Screentape gel image showing the ribosomal RNA bands from the RNA used for library
preparation. The RINe number, and indicator of RNA integrity, is shown at the bottom of the gel
image. B. High Sensitivity DNA Screentape image of the RNA-seq libraries. The cell lines are
indicated at the bottom, and treatment with 1 µg/mL tetracycline or mock treatment is indicated
below the individual samples.
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4.2.2 Alignment of RNA-Seq Data
TopHat2 (Kim et al., 2013) was used to align FASTQ files derived from RNA-Seq raw
data to the hg19 human reference genome. Alignment statistics for the 8 individual samples are
presented in Table 4.1. All samples showed a high rate of alignment to the human reference
genome (See table 4.1). The output of Tophat2 is a .BAM file, which can be displayed graphically
as alignments on the human genome. Furthermore, there .BAM files can be used to make a
coverage track, which sums the number of reads aligning to a given base in the reference genome.
These genome coverage tracks can be accessed through the UCSC genome browser.
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Sample

ARGL ARGL ARGL ARGL
CAT - CAT CAT
CAT
U1 –
U1 U1
U1
Tet
Tet
+Tet
+Tet
Tet
Tet
+Tet
+Tet
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
Rep 1
Rep 2
4.41E+ 7.07E+ 4.36E+ 4.37E+ 3.51E+ 5.16E+ 4.36E+ 4.07E+
07
07
07
07
07
07
07
07
3.84E+ 6.12E+ 3.72E+ 3.80E+ 3.04E+ 4.52E+ 3.78E+ 3.56E+
07
07
07
07
07
07
07
07
87.00% 86.58% 85.24% 86.91% 86.83% 87.53% 86.73% 87.50%

Left Reads
total
Left reads
mapped
% of input
Left
4.30E+ 7.35E+ 4.69E+ 4.59E+ 3.34E+
multiple
06
06
06
06
06
alignment
% multiple
11.21% 12.02% 12.61% 12.09% 10.96%
alignment
Right reads 4.41E+ 7.07E+ 4.36E+ 4.37E+ 3.51E+
07
07
07
07
07
total
Right Reads 3.81E+ 6.07E+ 3.69E+ 3.77E+ 3.02E+
07
07
07
07
07
Mapped
% of input 86.36% 85.95% 84.65% 86.26% 86.10%
Right
4.38E+ 7.45E+ 4.75E+ 4.65E+ 3.39E+
multiple
06
06
06
06
06
alignments
% multiple
11.49% 14.27% 12.87% 12.34% 11.23%
alignment
3.74E+ 5.97E+ 3.63E+ 3.71E+ 2.97E+
Aligned
07
07
07
07
07
Pairs
Paired
3.17E+ 5.44E+ 3.51E+ 3.43E+ 2.45E+
Multiple
06
06
06
06
06
Alignments
Discordant
3.52E+ 5.96E+ 3.94E+ 3.80E+ 2.79E+
Aligned
05
05
05
05
05
Pairs
%
Concordant
84.09% 83.61% 84.24% 83.96% 83.85%
Pair
Alignment
Table 4.1 Alignment statistics for the 8 samples sequenced.
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5.50E+
06

4.46E+
06

4.13E+
06

12.17% 11.80% 11.60%
5.16E+ 4.36E+ 4.07E+
07
07
07
4.49E+ 3.76E+ 3.53E+
07
07
07
86.96% 86.17% 86.73%
5.60E+
06

4.53E+
06

4.20E+
06

12.47% 12.05% 11.89%
4.41E+
07

3.69E+
07

3.47E+
07

4.08E+
06

3.33E+
06

3.05E+
06

4.45E+
05

3.69E+
05

3.30E+
05

84.52% 83.77% 84.45%

4.2.3 Overexpression of ARGLU1 alters the abundance of a number of genes
I utilized the RNA-seq statistical package Cuffdiff (Trapnell et al., 2013), which is
incorporated in the Cufflinks suite of RNA-seq analysis tools (Trapnell et al., 2010), to
quantitatively compare the alignments derived from TopHat on a gene and isoform level. Cuffdiff
generates uses a measure known as Fragments Per Kilobase of transcript per Million reads mapped
(FPKM), which allows for comparisons of transcript levels between samples. Based on the
Cuffdiff output, 16 genes were significantly upregulated in the ARGLU1 +Tet group compared
with all three control groups. A further 8 genes were upregulated in the ARGLU1 +Tet group
compared with the CAT +Tet and ARGLU1 –Tet groups. There were substantially more genes
downregulated following ARGLU1 overexpression, with 107 genes downregulated following in
the ARGLU1 +Tet group compared with all three control groups, and 54 genes downregulated
compared with the CAT +Tet and ARGLU1 –Tet groups. These genes are listed in Table 4.2.
To determine if there was any enrichment of genes with similar molecular function, I used
the list of up- and downregulated genes to query the DAVID functional annotation tool (Table
4.3). I found that the most highly enriched molecular function was catalytic activity, indicating
that ARGLU1 seems to be regulating the expression levels of enzymes. Two other enriched
molecular functions were the categories lyase and hydrolase.
To validate the Cuffdiff findings of genes that were upregulated and downregulated, I
performed semi-quantitative RT-PCR for selected. I found that when RT-PCR was performed on
duplicate samples from ARGLU1 –Tet and ARGLU1 +Tet cells, these RT-PCR reactions followed
the trends observed in by Cuffdiff analysis (Figure 4.3A and B). Interestingly, two genes involved
in paraspeckles, PSPC1 and the lncRNA NEAT1, were both downregulated upon ARGLU1
overexpression (Figure 4.3B)
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Upregulated Significantly in ARGLU1 +Tet compared to
3 groups
ABHD16A
ARGLU1
ATF7IP2
BTN3A2

BTN3A3
C21orf140
CCNH
CHPF2

DDX39A
FBXL5
N6AMT1
OVGP1

RIMKLB
SNRPA1
SRSF2
TNFRSF10D

Upregulated in ARGLU1
+Tet compared to both CAT
+Tet and ARGLU1 -Tet
CMTR2
TCP10L
COQ2
ZNF117
MOSPD2
ZNF223
NAPB
ZSCAN12P1

Downregulated in ARGLU1
+Tet compared to both CAT
+Tet and ARGLU1 -Tet
ABHD14B
FAM86B1 MIR4435-1HG
SAT1
ABCA2
MXRA8
ACYP1
FAM86FP
MPC1
SERPINB1
ABHD16B
NAGLU
AIG1
FAM86HP
MRPL1
SFXN2
ATHL1
NAT14
ANKRD29
FBXL4
NEAT1
SHISA4
C17orf70
NDUFV3
AP1S2
GALT
NIPSNAP3A
SIGMAR1
C1QTNF6
NPTXR
APTX
GATS
NPL
SLC35G1
CBS
NUDT18
ASB16-AS1
GDAP1
NRBP2
SLC5A3
CCNL2
NUDT8
ASIC1
GNE
PCYOX1L
SMARCD3
CENPM
OCEL1
ATP5G1
H6PD
PEX7
STYXL1
CYB5D2
PAPLN
ATP7B
HAGHL
PIGV
TCTA
D2HGDH
PCBP4
ATPAF2
HDHD2
PIGX
TCTN1
DNPH1
PCK2
C22orf29
HGSNAT
PM20D2
TDRP
DPYSL4
PHF7
C22orf39
HMGCL
PPCDC
THBS3
FAM132B
PIGQ
CBR4
HOXC-AS1
PPCS
THSD4
GALNT16
PPM1M
CCDC53
HSD17B8
PPFIA4
TMCC1-AS1
HINT2
PYCRL
CDHR1
IFT88
PPM1N
TMEM187
IDH2
RPUSD3
CLN5
IGDCC4
PPP1R21
TUSC3
IL17RC
SEMA6C
COL4A4
LINC00152
PRAF2
TXNRD3
KIAA0141
SH3GLB2
COL4A5
LINC00173
PRELID2
TYSND1
LOC100129534
SPATA20
DDIT4
LINC01004
PSPC1
UCP2
LOC101927667
SPC24
DDT
LINC01184
RBM3
UNC119B
LTBP4
ST3GAL3
DENND5B LINC01355
RBPMS2
UNK
MAPK11
TMEM219
DHRS11
LYRM1
RHBDD2
UQCC2
MAPK12
TMEM42
DOK3
LYRM9
RNF216P1
UROS
MC1R
TPCN1
EMC3-AS1
LZTS3
RRAGB
WDR31
MFSD3
TRAPPC6A
EPHX1
METTL21B
RRM2
WEE1
MMP24-AS1
TTC38
EPHX2
MGC72080
RWDD2B
MORN1
ZNF586
Table 4.2 Genes significantly upregulated and downregulated in ARGLU1 +Tet group
Downregulated Significantly in ARGLU1 +Tet
compared to 3 groups

compared to controls.
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Category

Term

Count

P
Value

Fold
Enrichment

Benjamini

FDR

Genes

Molecular
Function

catalytic
activity

67

1.83E-08

1.77E+00

5.90E-06

2.48E
-05

HGSNAT, SAT1, SPATA20,
D2HGDH, TUSC3, LTBP4,
HINT2, PPCS, CHPF2, N6AMT1,
ST3GAL3, MC1R, ACYP1,
HMGCL, NUDT18, PCYOX1L,
CCNH, RPUSD3, PIGV, APTX,
CBR4, SIGMAR1, PIGQ, WEE1,
COQ2, H6PD, RRM2, TYSND1,
DDT, FBXL5, TXNRD3, PPM1N,
HAGHL, PPM1M, NRBP2,
PYCRL, STYXL1, NAGLU, GNE,
UROS, ATHL1, ABCA2,
ATP5G1, PPCDC, NUDT8, IDH2,
NAT14, HSD17B8, OVGP1,
PM20D2, DHRS11, NPL, GALT,
EPHX2, EPHX1, DPYSL4,
ABHD14B, PAPLN, MAPK11,
PCK2, RIMKLB, NDUFV3,
MAPK12, THSD4, HDHD2,
ATP7B, CBS

Molecular
Function

carboncarbon
lyase
activity

5

2.30E-04

1.64E+01

3.64E-02

3.11E
-01

DDT, NPL, PPCDC, PCK2,
HMGCL

Molecular
Function

lyase
activity

7

7.75E-04

6.38E+00

7.99E-02

1.04E
+00

DDT, NPL, UROS, PPCDC,
PCK2, HMGCL, CBS

Molecular
Function

manganese
ion binding

7

8.59E-04

6.26E+00

6.68E-02

1.15E
+00

NUDT18, NUDT8, PPM1N, IDH2,
PPM1M, PCK2, RIMKLB

Molecular
Function

cofactor
binding

7

0.00922

3.87E+00

4.49E-01

1.18E
+01

D2HGDH, TXNRD3, UROS,
IDH2, CBR4, HMGCL, CBS
STYXL1, NAGLU, HINT2,
ATHL1, ABCA2, ATP5G1,
MC1R, NUDT8, ACYP1,
NUDT18, OVGP1, CCNH,
PM20D2, EPHX2, DPYSL4,
APTX, EPHX1, PAPLN,
ABHD14B, H6PD, TYSND1,
THSD4, PPM1N, HDHD2,
HAGHL, PPM1M, ATP7B
NUDT18, MAPK12, NUDT8,
EPHX2, PPM1N, IDH2, PPM1M,
WEE1, ATP7B
NDUFV3, PYCRL, D2HGDH,
PCYOX1L, H6PD, RRM2,
DHRS11, TXNRD3, IDH2, CBR4,
HSD17B8

Molecular
Function

hydrolase
activity

27

0.0102

1.63E+00

4.26E-01

1.30E
+01

Molecular
Function

magnesium
ion binding

9

0.0163

2.74E+00

5.31E-01

2.00E
+01

Molecular
Function

oxidoreduct
ase activity

11

0.0266

4.20E+00

6.63E-01

3.06E
+01

Molecular
Function

coenzyme
binding

5

0.0417

3.80E+00

7.83E-01

4.38E
+01

D2HGDH, TXNRD3, IDH2,
CBR4, HMGCL

6.53E
+01

SAT1, HGSNAT, TUSC3, GNE,
CCNH, LTBP4, HINT2, PIGV,
GALT, MAPK11, CHPF2, PIGQ,
WEE1, N6AMT1, ST3GAL3,
COQ2, MAPK12, NAT14, NRBP2

Molecular
Function

transferase
activity

19

0.0754

1.49E+00

9.20E-01

Table 4.3 Molecular Function GO analysis of genes significantly upregulated and
downregulated following ARGLU1 overexpression.
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Figure 4.3 Semi-Quantitative RT-PCR confirms upregulated and downregulated genes
following ARGLU1 overexpression. A. RT-PCR was performed for the indicated genes. B.
RT-PCR was performed for the paraspeckle components PSPC1 and NEAT1. For all samples,
lanes 1 and 2 are duplicate samples from mock treated ARGLU1-TO cells, while lanes 3 and 4
are duplicate samples from ARGLU1-TO cells treated with 1 ug/mL tetracycline.
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4.2.4 Overexpression of ARGLU1 causes alternative splicing of a number of genes
Besides assessing gene level differences in expression, Cuffdiff is also able to create
expression profiles for individual isoforms of expressed genes, thus allowing for an analysis of
alternative splicing. To this end, I queried the differential splicing Cuffdiff output for genes that
were significantly alternatively spliced. I have summarized these findings in Table 4.4. Notably
this is a much smaller list. This may be explained by the fact that each group only contained two
replicates. Cuffdiff generally requires three replicates for each group to make alternative splicing
predictions. This program may not be able to generate robust alternative splicing results with only
two replicates. Furthermore, there were many more alternative splicing events that were annotated
between ARGLU1 +Tet and the CAT +/- Tet samples that may not have risen to the level of
significance in the ARLGU1 –Tet sample because only two samples were used, or because there
was some basal ARGLU1 expression in the absence of tetracycline that confounded these results.
I used the alternatively spliced Cuffdiff output to query the DAVID functional annotation
tool to determine enrichment in molecular function (Table 4.5). Notable molecular functions
included oxoreductase activity, cation binding, and cytoskeletal components.
In order to validate the alternative splicing predicted, I performed RT-PCR using primers
that would include the alternative splicing event by crossing multiple exons, including alternative
exons. RT-PCR indicated that alternative splicing found in the selected genes could be replicated
using an alternative measure (Figure 4.4).
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Significantly Alternatively Spliced in ARGLU1 +Tet
compared to 3 control groups

Significantly Alternatively
Spliced in ARGLU1 +Tet
compared to both CAT +Tet
and ARGLU1 -Tet

AK2

FGFR2

NFATC1

SERPINB
1

ADD3

BAG6

GPR98

NIN

SLC25A1

AGER

BUB3
C8orf59
CDC42EP
3

HIBCH
IL17RC

NUDT7
P4HA2

STAG2
TCF19

KDM6A

PAX6

TUSC3

ALOX5
AOC3
BTN3A
3

CEP131

KIAA0319

PPARGC1
B

UNK

CA12

RPH3AL

NUDT7

DEPDC1

MIS12

PRMT2

URI1

INCEN
P

SLC26A6

PLCB3

DPH3

MORF4L2
MRPS6,SLC5A
3

RALGPS2

YIPF1

RFC5

ZNF207

DTNA

ITPR1
LAMTOR
3
PCDH7
PMS1
RASSF7

SYTL5
UBE2Q2
ZNF430
ZNF438
FAM63
A

EPB41L4
MYO1B
RFX3
ZXDC
B
ETV1
NDUFV3
SAMD4A
Table 4.4 Genes found to be significantly alternatively spliced in the ARGLU1 +Tet group.
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Category

Term

Count

P
Value

Fold
Enrichment

Benjamini

FDR

Genes

Molecular
Function

oxidoreductase
activity, acting on
single donors with
incorporation of
molecular oxygen

3

0.0254

1.19E+01

9.08E-01

27.27

KDM6A, P4HA2, ALOX5

Molecular
Function

metal ion binding

23

0.0298

1.47E+00

8.45E-01

31.22

Molecular
Function

cation binding

23

0.0331

1.46E+00

7.89E-01

34.03

Molecular
Function

cytoskeletal protein
binding

6

0.0376

3.15E+00

7.58E-01

37.75

Molecular
Function

ion binding

23

0.0388

1.44E+00

7.05E-01

38.73

Molecular
Function

calcium ion binding

8

0.0506

2.31E+00

7.46E-01

47.39

Molecular
Function

transition metal ion
binding

16

0.0736

1.52E+00

8.29E-01

61.15

SLC5A3, KDM6A, ZNF430,
CA12, ZXDC, RPH3AL, DPH3,
PCDH7, ITPR1, GPR98,
ZNF207, SLC26A6, PLCB3,
P4HA2, NUDT7, SYTL5,
TCF19, UNK, ALOX5, ZNF438,
ADD3, DTNA, AOC3
SLC5A3, KDM6A, ZNF430,
CA12, ZXDC, RPH3AL, DPH3,
PCDH7, ITPR1, GPR98,
ZNF207, SLC26A6, PLCB3,
P4HA2, NUDT7, SYTL5,
TCF19, UNK, ALOX5, ZNF438,
ADD3, DTNA, AOC3
MYO1B, RPH3AL, EPB41L4B,
ADD3, CDC42EP3, GPR98
SLC5A3, KDM6A, ZNF430,
CA12, ZXDC, RPH3AL, DPH3,
PCDH7, ITPR1, GPR98,
ZNF207, SLC26A6, PLCB3,
P4HA2, NUDT7, SYTL5,
TCF19, UNK, ALOX5, ZNF438,
ADD3, DTNA, AOC3
SLC26A6, PLCB3, PCDH7,
ALOX5, ITPR1, GPR98, DTNA,
AOC3
KDM6A, ZNF430, CA12,
ZXDC, RPH3AL, DPH3,
ZNF207, P4HA2, NUDT7,
SYTL5, TCF19, ALOX5, UNK,
ZNF438, DTNA, AOC3

Table 4.5 Molecular function Gene Ontology of genes with significant alternative splicing
following ARGLU1 overexpression.
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Figure 4.4 Validation of alternative splicing following ARGLU1 overexpression. A. Splicing
sensitive RT-PCR for the c8orf59 transcript. B. Splicing sensitive RT-PCR for MORF4L2. C.
Splicing sensitive RT-PCR for ACYP1.

D. Splicing sensitive RT-PCR for URI.

For all

experiments, lanes 1 and 2 are duplicate samples from mock treated ARGLU1-TO cells, while
lanes 3 and 4 are duplicate samples from ARGLU1-TO cells treated with 1 ug/mL tetracycline.
For all tested events, the UCSC browser track for this alternative splicing event as well as a cartoon
depiction of the alternative splicing event is noted. Primers are indicated by black arrows beneath
the cartoon.
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4.3 Conclusion
In this chapter I have assessed the transcriptome-wide effect of ARGLU1 overexpression.
I found that a number of genes are upregulated and downregulated following inducible
overexpression of ARGLU1. These genes are enriched for Gene Ontology categories including
catalytic activity and ion binding. Furthermore, a number of genes were found to be alternatively
spliced by Cuffdiff analysis, despite technical shortcomings resulting from the use of two RNAseq replicates per group rather than three. I was able to validate the findings from RNA-Seq for a
number of genes using RT-PCR to assess both expression level as well as alternative splicing.
Overexpression may not represent the ideal condition for assessing transcriptional and
splicing events regulated by ARGLU1. A better system may be to look at cells in which ARGLU1
has been knocked out. I will address methods to generate these results in the next chapter.
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4.4 Materials and Methods
Cell Culture
HEK 293-Flp-In TRex cells were maintained in DMEM with 10% FBS and 100 U/mL PenicillinStreptomycin. Cells in which the pcDNA5/FRT vector had been integrated were additionally
maintained in media supplemented with Blastcidin and Hygromycin B. Induction of protein
expression was performed by supplementing DMEM/Blast/Hygromycin media with 1 ug/mL
tetracycline.
Western blotting
Cells were lysed for 30 minutes in ice cold RIPA buffer supplemented with protease inhibitors and
benzonase. Protein was quantified using the BioRad Cell lysates were then mixed with 2X
Laemmli’s SDS loading buffer with 10 mM DTT. 30 µg of protein was loaded into SDS-PAGE
gels and resolved at 100V. Transfer to nitrocellulose membrane was carried out in Tris-glycine
buffer with 10% methanol at 4°C at 240 mA for 2 hour. Membranes were blocked with Licor
blocking buffer for 1 hr at room temperature. Blots were then incubated overnight at 4°C with
primary antibody diluted in Licor blocking buffer supplemented with 0.1% tween-20. Membrane
was then washed with TBS-0.1% tween 3 times for five minutes. Appropriate florescent labeled
secondary antibodies diluted in Licor blocking buffer with 0.1% tween and 0.01% SDS were
incubated with the membrane for 45 minutes at room temperature with rocking. Membrane was
then washed with TBS-0.1% tween 3 times for five minutes. Membranes were imaged on the
Licor Odyssey system.
Preparation of RNA
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RNA was prepared by lysing cells in an appropriate volume of Trizol (Life Tech). Chloroform
was added, mixed vigorously, and incubated on ice for 5 minutes. These samples were centrifuged
at maximum speed for 15 minutes. The aqueous phase was then mixed with 70% ethanol and
processed with the Purelink RNA mini kit according to the manufacturer’s instructions. RNAs
were treated with Purelink On-column DNase I.

RNA concentration was assessed using

Absorbance at 280 on a nanodrop spectrophotometer. 1 uL of RNA for library preparation was
run on the RNA Screentape on the tapestation machine.
RNA-Seq library generation
RNA was prepared for sequencing using the TruSeq Stranded mRNA Library Prep Kit from
Illumina according to the manufacturer’s direction. Briefly, poly(A) mRNA was selected with
two rounds of oligo-d(T) selection. RNA was then fragmented, and reverse transcription was
carried out using random primers. Second strand synthesis was then carried out, with dUTP in
place of dTTP. The ds-cDNA was then end repaired and A-tailed. Adaptors were then ligated.
Each sample was tagged with a unique barcode. Finally, libraries were amplified with 15 cycles
of PCR and purified away from the primers using Axyprep PCR cleanup kit (Axygen). The final
libraries were then quantified using Qubit 2.0 high sensitivity (Life Technologies). 1 uL of each
library was also run on the Tapestation instrument using a high sensitivity DNA Screentape
(Agilent). These results were used to calculate the molarity of the libraries. Sequencing libraries
were diluted to 2 nM and pooled. PhiX sequencing library was added at 5% of the pooled libraries.
Finally, the pooled library was prepared for sequencing on the NextSeq 500 using a 150 cycle high
output flow cell, with 2x76 read length.
Alignment
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After sequencing was complete, FASTQ files were generated and concatenated for each sample.
FASTQs were then aligned with the hg19 Human Genome Reference from UCSC using Tophat 2
to output genomic alignments in the form of .bam files. Accepted_hits.bam file for each sample
were then sorted using the samtools sort command, and indexed using the samtools index
command. These .bam files were then turned into genome coverage tracks using the bedtools
command genomeCoverageBed -bg -split –ibam. This genome coverage track was then used to
make a BigWig track with the command bedGraphToBigWig. These files were then used for
display on the UCSC genome browser.
Cuffdiff analysis
I ran Cuffdiff with the following command options:
cuffdiff -min-reps-for-js-test 1-L C_min,C_plus,A_min,A_plus -p 24 -library-type fr-firststrand
using the UCSC_hg19 genes.gtf file as a reference, which was obtained from the Tophat2 website
at https://ccb.jhu.edu/software/tophat/igenomes.shtml, accessed on 30 November, 2014.
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Chapter 5
Discussion and Future Directions
5.1 Discussion
In this dissertation, I have addressed a number of questions regarding the regulation and
regulatory function of the protein ARGLU1. The first question I addressed is the role of an
ultraconserved element (UCE) in the complex alternative splicing of ARGLU1 mRNA. These
experiments demonstrated that the ARGLU1 UCE is necessary and sufficient to induce intron
retention and inhibition of splicing. I next addressed the question of whether ARGLU1 protein
can regulate alternative splicing of its own mRNA. Indeed, overexpression of ARGLU1 causes a
rapid and dramatic shift in the splicing of endogenous ARGLU1 mRNA. Finally, using RNA-Seq,
I asked whether ARGLU1 protein can cause changes in splicing of other genes. I will now discuss
each of these findings to put them in the context of previous reports.
5.1.1 Cis-Element control of alternative splicing
Since alternative splicing was first described in the early 1980s (Alt et al., 1980; Early et
al., 1980), there have been efforts to understand the regulatory elements present within RNA
transcripts themselves that direct alternative splicing , and were known to interact with transfactors. As described earlier, these splicing regulatory elements (SREs) can be found in both
introns and exons, and can both enhance and suppress splicing (Braunschweig et al., 2013; Fu and
Ares, 2014; Wang and Burge, 2008).
In ARGLU1 alternative splicing, the cis-elements contained in the UCE seem to have a dual
role. One function is to suppress inclusion of the alternative exon. These elements are located
downstream of the alternative exon. The evidence for this is found in experiments in which three
95

25 bp deletion were made downstream of the alternative exon that increased the inclusion of the
alternative exon. Interestingly, these deletions also caused usage of 5’-splice sites other than the
annotated site for the alternative exon. Furthermore, mutation of GU dinucleotides (specifically
SS5 and SS6) downstream of the alternative exon caused a dramatic increase in splicing of exons
2 and 3. Therefore, there are a number of sequences in the downstream region that are acting as
intronic splicing silencers.
One model that I proposed for the inhibition of splicing between ARGLU1 exon 2-3 is the
presence of multiple competing 5’-splice sites following the alternative exon. It has been shown
that multiple 5’-splice sites, each engaged with U1 can cause inefficient recognition of the true 5’splice site and prevent the splicing reaction from proceeding past the E complex (Roca et al., 2013;
Sharma et al., 2005). Therefore, it is possible that the alternative exon is able to undergo exon
definition, but the presence of multiple 5’-splice sites interacting with the 3’-splice site of exon 3
causes stalling of the splicing reaction, which, if not resolved results in intron retention.
Another model, which is not mutually exclusive with the first model, is that the alternative
exon has very poor splice sites, which can engage with the splice sites of the upstream and
downstream exons, but result in an abortive splicing reaction, possibly because of the competition
for 5’-splice sites proposed in model 1. There is certainly evidence that the alternative exon splice
sites are weak, as mutation of these splice sites individually caused exclusive splicing to the
alternative exon.

Weak splice sites have been observed to be a common phenomenon in

alternatively spliced exons, as it allows for regulation through the interaction between cisregulatory elements and trans-regulatory factors (Sakabe and de Souza, 2007; Zhan, 2013). The
possible regulatory role of trans-acting factors will be discussed in the next section.
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5.1.2 ARGLU1 regulates its own alternative splicing—A new splicing trans-regulatory
element?
In Chapter 3, I presented evidence that overexpression of an ARGLU1 cDNA caused a
dramatic and rapid shift in the splicing of ARGLU1 mRNA away from exon 2-3 splicing toward
increased intron retention as well as increased inclusion of the alternative exon. Furthermore,
treatment with the translation inhibitor emetine caused an increase in the level of ARGLU1 spliced
isoform that correlated with a decrease in ARGLU1 protein levels. An additional insight into the
emetine treatment experiments is that under translational inhibition, levels of mRNA including the
alternative exon were increased, indicating that this transcript is most likely degraded by the
nonsense mediated decay pathway (NMD), as predicted.
Interestingly, very similar alternative splicing regulation has been seen in a number of
splicing factors, and are often associated with ultraconserved elements (Baek and Green, 2005;
Lareau et al., 2007; Ni et al., 2007; Sun et al., 2010; Sureau et al., 2001). Indeed, experiments very
similar to those I performed, in which SRSF1 (SF2/ASF) (Sun et al., 2010) or SRSF2 (SC35)
(Sureau et al., 2001) were overexpressed under exogenous control, found that these splicing factors
caused increased usage of alternative exons that induced NMD. Furthermore, SRSF1 has a number
of retained intron isoforms that are localized in the nucleus (Boutz et al., 2015; Sun et al., 2010).
The exact mechanism of ARGLU1 autoregulation is not clear from our experiments.
However, I will suggest a number of different models. First, ARGLU1 may bind directly to
sequences within the UCE or the flanking exons and cause a decrease in exon 2-3 spicing. This
could be caused by increased inhibition of this splicing event, or it could be the result of increased
exon 2-alt exon-exon 3 splicing. In chapter 3 I presented evidence that overexpression of
ARGLU1 protein causes increased splicing inclusion of the alternative exon which targeted it for
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NMD, however it is unclear exactly how much this splicing contributes to regulation of exon 2exon 3 splicing.
A second possible mechanism is that ARGLU1 is interacting with another splicing factor
to mediate alternative splicing. Multiple efforts to define the full complement of mRNA proteins
have not identified ARGLU1 as an RNA binding protein (Baltz et al., 2012; Castello et al., 2012).
It is known that the RS domains of SR proteins interact with other non-SR proteins, such as U170K, through their own RS domains (Wu and Maniatis, 1993). As I have shown in chapter 1,
ARGLU1 also contains an N-terminal domain multiple groups of SR dipeptides. Thus it is not
unreasonable to assume that ARGLU1 can interact with SR proteins as well as other proteins with
RS domains. In the context of ARGLU1 overexpression, this could have two effects. First, it
could allow for increased ARGLU1 recruitment to the RNA, possibly mediating further
interactions. Alternatively, it could interact with SR proteins or some other splicing regulator,
causing them to be removed from the RNA, thus squelching their function and altering splicing.
Either of these possible mechanisms can be extended to the transcriptome wide splicing
effects we observed in chapter 4. The small group of genes that were seen to be alternatively
spliced in chapter 4 may suggest that ARGLU1’s function is not on splicing. However, the analysis
of alternative splicing by Cuffdiff may have been somewhat limited by only having two
sequencing replicates while the Cuffdiff literature recommends three. Below, I will suggest a
number of experiments that should help clarify the mechanism of ARGLU1 alternative splicing
regulation and its larger cellular role.
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5.2 Future Directions
Based on the findings presented in this dissertation and the reports of others, I suggest that
ARGLU1 is a new SR-like protein that plays a role in alternative splicing. To further understand
the role that ARGLU1 plays in this process, I have described a number of lines of inquiry that
should be fruitful.
5.2.1 Knock out the UCE in an animal model
In this study I have presented evidence that the UCE located in intron 2 is important for
regulation of complex alternative splicing of ARGLU1¸ including the intron retention phenotype
as well as the inclusion of the alternative exon. The high level of sequence conservation, and the
demonstrated function of this sequence suggests that this regulation is quite important, and has
been under selective pressure through evolutionary time. Strikingly, these two alternative splicing
events seem to be conserved in other species, and most likely play a similar role. To address the
function of this UCE at an organismal level, a conditional or global knock out of the UCE sequence
in an animal model such as the mouse or even Xenopus would be of great interest to provide insight
into the evolutionary selective pressure that has preserved this sequence. Alternately, this could
be accomplished by the knock-in of a construct missing the UCE. Recent advances in genome
editing techniques, such as Cas9/CRISPR, should make generation of this mouse line fast and
efficient.
5.2.2 Knock out ARGLU1 in an animal model or cell line
As a complimentary experiment it will be of interest to examine the knock out mouse of
ARGLU1 protein. The International Mouse Phenotyping Consortium has generated a number of
constructs that would be of great use for understanding the expression of ARGLU1 as well as its
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cellular and development role. These knockouts exist as ES cells that can be used different ways.
The knock-out scheme used provides the ability to use LacZ as a gene trap to assess the distribution
of expression as well as the conditional knock-out potential. This would provide a useful tool for
understanding the developmental and tissue specific role that ARGLU1 plays, as well as answering
the question of whether ARGLU1 is important for cellular viability or animal development.
Furthermore, the presence of a floxed allele in an ES cell line would allow for the introduction of
knock-in alleles, including the knock-in of a construct missing the UCE, as discussed previously.
Finally, this could allow for the production of ARGLU1 knock-out cell lines, which could be useful
for performing experiments such as RNA-seq by directly comparing identical cell types.
Instead of using a mouse system to knock out ARGLU1, another tractable method would
be to use the Cas9/CRISPR technology discussed previously to induce targeted double-stranded
breaks, which will then be repaired by non-homologous end joining to cause insertions and
deletions, causing a knock out of the gene. These cell lines could then be used to assess the
functional role of ARLGU1. One key experiment that should be performed with ARGLU1 cell
knockouts is RNA-seq. Often, decreased expression of proteins is much more informative than
overexpression, especially if the protein is already fairly highly expressed. Additionally, RNASeq from a knock-out cell line would allow for a comparison to RNA-Seq results from the
ARGLU1 over-expressing cells.

I am currently screening cells transduced with lentivirus

expressing cas9 that can be selected with puromycin along with a number of sgRNAs targeting the
first and second exon of ARGLU1. I am hoping to find cells in which the ARGLU1 protein is not
expressed. These cells can then be used for further experiments to test the cellular response to the
lack of ARGLU1, such as analysis of ARGLU1 mRNA splicing or global changes in mRNA
expression and splicing.
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5.2.3 Experiments using the inducible ARGLU1 system
I have generated a number of resources that will be useful for further experiments to
understand the role of ARGLU1. First, I have generated cell lines that allow for inducible
expression of ARGLU1, as well as an HA tagged versions of the protein. This tag allows for the
specific immunoprecipitation of this protein. I would suggest that this will be important for a
number of experiments.
Deletion of protein domains or mutation of individual amino acids in the inducible ARGLU1
First, I would suggest a closer interrogation of the ARGLU1 protein domains necessary
for regulation of its own splicing. I have already cloned an HA-tagged ARGLU1 cDNA into the
pcDNA5/FRT/TO plasmid, thus making deletions in the protein and overexpressing them in cells
should be feasible. Furthermore, a number of serines in the RS domain of ARGLU1 has been
shown to be phosphorylated (Varjosalo et al., 2013). Phosphorylation of the RS domains in SR
proteins are known to be important for their function and subcellular localization (Aubol et al.,
2013; Cáceres et al., 1997). Thus mutation of these serines may give some insight into their
function in ARGLU1.
RNA-Immunoprecipitation based experiments
Second, if ARGLU1 is indeed important in splicing, a key experiment will be to determine
what RNAs ARGLU1 is targeted to. To accomplish this, it would be useful to perform RIP-seq
(Townley-Tilson et al., 2006), in which immunoprecipitation of ARGLU1 would be followed by
preparation of RNA-seq libraries to determine the population of RNAs that are associated with
ARGLU1. This experiment should be greatly aided by having an HA tagged protein, as there are
commercially available anti-HA antibodies that work well for immunoprecipitation. Possible
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pitfalls of this approach are that the interaction between ARGLU1 and its targets may be transitory,
as well as the possibility of non-physiological interactions taking place after cell lysis, leading to
increased background (Mili and Steitz, 2004). Another approach to identifying ARGLU1interacting RNAs is to use CLIP-seq, in which proteins and RNAs are cross-linked with either UV
(Licatalosi et al., 2008; Ule et al., 2003), or formaldehyde (Silverman et al., 2014). Notably, UV
crosslinking will only create protein-RNA and RNA-RNA crosslinks, and will cause proteinprotein interactions. If ARGLU1 is not an RNA binding protein but instead functions through
protein-protein interactions, UV crosslinking will not be a viable method of determining the
population of bound RNAs.
Purification of ARGLU1 containing complexes
A third important use for a system to induce expression of tagged ARGLU1 is to affinity
purify the proteins that ARGLU1 binds to. I have carried out initial experiments using a polyclonal
antibody against ARGLU1, indicating that there is a limited number of proteins bound to
ARGLU1. However, a high affinity tag or two-step purification process may represent a better
system to purify ARGLU1-containing protein complexes.

So far other studies have only

tangentially tied ARGLU1 to either the mediator complex (Zhang et al., 2011) or the spliceosome
(Behzadnia et al., 2007; Deckert et al., 2006; Hegele et al., 2012). Proteomic analysis of ARGLU1
protein-protein interactions should help resolve the uncertainty about ARGLU1’s molecular
function. Other biochemical studies of ARGLU1 will also be helpful in purifying the protein and
its associated complexes. For example, use of a protein size exclusion columns or sucrose
sedimentation, followed by immunoblotting, may further facilitate characterization and
purification of ARGLU1-containing complexes.
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I have identified ARGLU1 as regulating the splicing of a number of transcripts, including
the homeostatic splicing of its own transcript. However, as alternative splicing is a highly complex
process, it is highly unlikely that ARGLU1 alone is causing this alternative splicing. Finding other
proteins that regulate the splicing may be accomplished by a number of methods. First, siRNA or
shRNA mediated knock down of a large number of RNA binding proteins has been a useful tool
for identifying splicing events regulated by those proteins (Pandit et al., 2013; Park et al., 2004;
Saltzman et al., 2011). Indeed, Saltzman et al. knocked down SRSF1 and saw decreased levels of
alternative exon and increased levels of exon2-exon3 splicing in ARGLU1 mRNA (Saltzman et
al., 2011 supplmental table 1). Thus, further high throughput studies of RNA binding proteins
may provide useful information on proteins regulating alternative splicing of ARGLU1. A second
method may be to use RNA from the UCE to identify proteins bound to this region. I have
previously carried out preliminary studies using an aptamer tagged version of portions of the
ARGLU1 UCE to affinity purify proteins bound to this sequence, and identify them using mass
spectrometry. However, these results have not yet been functionally validated.
Fluorescent tagging to identify subcellular localization
Yet another use of the inducible expression system will be to investigate the subcellular
localization of ARGLU1. Previous studies have indicated that ARGLU1 can shuttle between the
nucleus and cytoplasm in a cell cycle dependent manner (Sigal et al., 2006). I would propose an
experiment in which an inducible ARGLU1 is tagged with a fluorescent protein. A pulse chase
experiment could then be performed to track ARGLU1’s cellular localization over time.
Furthermore, if combined with mutation of the serines in the RS domain, this may be a useful
system to identify residues important for this nuclear/cytoplasmic shuttling.
In vitro splicing of ARGLU1
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It may be of interest to make a smaller splicing reporter that can be used for in vitro
splicing. This will be useful for a number of reasons. It would allow for an analysis of the
spliceosomal complex at which ARGLU1 splicing is stalled. However, this type of splicing
reporter may be hard to construct, as I have shown that a large region of the UCE (approximately
150 nucleotides) is necessary for intron retention, and in vitro splicing is inefficient across introns
larger than 250 bases.
Analysis of the other highly conserved region of the A23 intron
Besides the UCE I have investigated in this report, ARGLU1 intron 2 also contains another
long, highly conserved region (although not as highly conserved as the UCE). It is possible that
this sequence also plays a role in ARGLU1 splicing.
Non-splicing related functions for ARGLU1 UCE
I have shown that there are sequences within the ARGLU1 UCE that do not appear to
function in regulation of ARGLU1 alternative splicing. It is not immediately clear what the
function of these sequences is or why they are so highly conserved. One possible role may be as
a nuclear rentention signal for the unspliced ARGLU1 RNA. However, further experiments will
be needed to understand fully the function of the ARGLU1 UCE.
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Appendix A
Name

Sequence

ARGLU1 Ex 2.2

GGAAGAAACAGCACGAAGAGT

ARGLU1 3 UTR R2

GCAGAGCATAGCCCCTATTAGA

ARGLU1 Exon 2 F

TGGTAGCAAAAAGGGTGGAG

ARGLU1 Exon 3 R

CAGTTTGGCTTGTGCTTCTG

ARGLU1 Exon 4 R

ACAGTTTTGGCCTGGACTTC

ARGLU1 UCE 504 F

AATTGTCAACATCTGAATGTTAAGTCC

ARGLU1 UCE 504 R

CTTTAATATCACACAAATCAACAAGG

ARGLU1 Alt F

AAGCTGGCGCGTATGGCAG

ARGLU1 ret F

TTTGGACTGGGAGGGATGA

ARGLU1 ret R

AGGCAGAACCCAACACTGAA

pcDNA3F

TCACTATAGGGAGACCCAAGC

pcDNA3R

CTGATCAGCGAGCTCTAGCA

Actin F

GGACTTCGAGCAAGAGATGG

Actin R

AGCACTGTGTTGGCGTACAG

CRISPR sgRNA
sequences
CRISPR sgRNA 1

AAAGAGGAAGCTGGCGCGTA

CRISPR sgRNA 2

GCTGGCGCGTATGGCAGCCG

Mutagenesis primers
F

R

A23mutAlt3’

CTTCCTGGCGCGTATGGCAGCC

GAGATTAAAATGATTTGTACTGTTAGCTTG
GCAATACC

A23mutAlt5’

GGACAAGACACAAAATATTCAACTTTT
AATGCTGATTAAAG

AGTGTCCTGCAGAGTGTG
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SS1 GC-CC

AACTTTTAATCCTGATTAAAGGAGTAT
AG

GAATATTTACTGTCTTGTCCAG

SS2 GT-CA

GATTAAAGGACAATAGGTAAAGAATA
CGTAGGTATAC

AGCATTAAAAGTTGAATATTTACTG

SS3 GT-CA

AGGAGTATAGCAAAAGAATACGTAGG
TATAC

TTAATCAGCATTAAAAGTTGAATATTTAC

SS4 GT-CA

TAAAGAATACCAAGGTATACATAATTG CCTATACTCCTTTAATCAGC
GTGAG

SS5 GT-CA

GAATACGTAGCAATACATAATTGGTGA TTTACCTATACTCCTTTAATCAG
G

SS6 GT-CA

TACATAATTGCAGAGACAAATATTCAC TACCTACGTATTCTTTACCTATAC
TTTATTTATATTTTATATATTATTTTTTT
AATTTG

SS1-3 mut

GACAATAGCAAAAGAATACGTAGGTA
TACATAATTG

CTTTAATCAGGATTAAAAGTTGAATATTTA
CTGTCTTG

SS4-6 mut

ATAATTGCAGAGACAAATATTCACTTT
ATTTATATTTTATATATTATTTTTTTAA
TTTG

GTATTGCTTGGTATTCTTTACCTATACTCCT
TTAATC

Ex2SS cons

aagtCTCGGTCGTTTGGAAAGTAG

acctgTCTAGCTTTTTGTGCGGC

Ex3SS cons

cttccagGAGGAAGAACGTGCAAAAC

aaagagaATGTTAAGATATTAGAAAAACAAAA
TG

crp3' cons

tccaggagAAGCTGGCGCGTATGGCA

agaaagagaGTACTGTTAGCTTGGCAATACCTG

crp5' cons

aagtATTCAACTTTTAATGCTGATTAAAG
G

acctgCTTGTCCAGTGTCCTGCAG

F

R

25 del 1 primers

AACATCTGCATTCCTCAG

AATTCATCATTCCTAAGGCAAAC

25 del 2 primers

TTCCTTGTATGTTGTTTCTTTATAAATG

TATGGTAAGAAGGAACAAAAAATG

25 del 3 primers

ATGGTTGAGCTGCTGATG

GGCTGAGCTGAGGAATGC

25 del 4 primers

TGCCAAGCTAACAGTACAAATC

TTATAAAGAAACAACATACAAGGAAG

25 del 5 primers

TTAAAGAGGAAGCTGGCG

ATACCTGCATCAGCAGCTC

25 del 6 primers

CAGCCGAGGAGCACACTC

AATGATTTGTACTGTTAGCTTGGC

25 del 7 primers

CACTGGACAAGACAGTAAATATTCAA
CTTTTAATG

CCATACGCGCCAGCTTCC

25 del 8 primers

ACTTTTAATGCTGATTAAAGGAGTATA
G

TCCTGCAGAGTGTGCTCC

25 del 9 primers

TAGGTAAAGAATACGTAGGTATAC

TGAATATTTACTGTCTTGTCC

25 del 10 primers

TAATTGGTGAGACAAATATTCAC

TACTCCTTTAATCAGCATTAAAAG

25 del 11 primers

TATTTATATTTTATATATTATTTTTTTA
ATTTGGTAAATAC

TGTATACCTACGTATTCTTTAC

25 del 12 primers

TTAATTTGGTAAATACTATCCAGTTTT
G

AAGTGAATATTTGTCTCACC
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25 del 13 primers

TTGTAGTTGTCCTTGTTGATTTG

AAAAATAATATATAAAATATAAATAAAGT
GAATATTTG

25 del 14 primers

TGATATTAAAGTATTAGTAATAATTGC
CAG

AACTGGATAGTATTTACCAAATTAAAAAAA
TAATATATAAAATATAAATAAAG

25 del 15 primers

GCCAGGAAACTATCATTAG

CACAAATCAACAAGGACAAC

25 del 16 primers

TTTAGTTGGTTGCTGTTTG

AATTATTACTAATACTTTAATATCACAC

UCE del 504

TATTAGTAATAATTGCCAGGAAAC

GGAAGGCAGCTTATATTG

A23ContDel

CAAGCCATCAAGCAGTCTTC

ACACTCAGGGCTGTAAAG

A23 168 del 1

AACATCTGCATTCCTCAG

GGAAGGCAGCTTATATTG

A23 168 del 2

ATATTCAACTTTTAATGCTGATTAAAG

TATGGTAAGAAGGAACAAAAAATG

A23 168 del 3

TATTAGTAATAATTGCCAGGAAAC

TTACTGTCTTGTCCAGTG
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